Document:

EX-10.34

 Exhibit 10.34 

Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats
as private or confidential. [***] indicates that information has been omitted. 
 ASSIGNMENT, LICENSE & SERVICES
AGREEMENT 
 This ASSIGNMENT, LICENSE & SERVICES AGREEMENT (this “Agreement”) is made by and between PEAR
THERAPEUTICS, INC., a Delaware corporation with offices at 745 Atlantic Ave., Boston, MA 02111 (“Pear ”), and BEHEALTH
SOLUTIONS, LLC, a Virginia limited liability company with offices at 375 Greenbrier Drive, Charlottesville, VA 22901 (“BeHealth”), effective as of March 24, 2018 (the “Effective Date”), for
the purpose of (i) transferring to Pear all of BeHealth’s right, title and interest in and to the Assigned Assets (as defined below), (ii) otherwise granting Pear a license under certain related intellectual property and proprietary rights
retained by BeHealth related to the Assigned Assets, and (iii) obtaining BeHealth’s assistance and services in connection with the Assigned Assets after the Effective Date. 

WHEREAS, Pear desires to include along with the Assigned Assets certain Critical Data (as defined below) rights under BeHealth’s agreements with the
University of Virginia and other educational institutions in relation to the Assigned Assets; 
 NOW, THEREFORE, in consideration of the mutual obligations
specified in this Agreement, the parties agree to the following: 
 1. Definitions. The defined terms used in this Agreement shall have the meanings
set forth herein or as defined in this Section 1. 
 1.1. “Affiliate” means, with respect to a party, any entity or
person that controls, is controlled by, or is under common control with that party. For the purpose of this definition, “control” or “controlled” means direct or indirect ownership of fifty percent (50%) or more of the shares of
stock entitled to vote for the election of directors in the case of a corporation or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity, or any other arrangement whereby the entity or person controls or
has the right to control the board of directors or equivalent governing body of a corporation or other entity or the ability to cause the direction of the management or policies of a corporation or other entity. 

1.2. “Assigned Assets” means collectively, the Software, Documentation, the Assigned Contracts, the SHUTi Logo and related
SHUTi marks, the Know-How related thereto owned by BeHealth, and all other Intellectual Property Rights and Data in and to the foregoing owned by BeHealth. 

1.3. “Assigned Contracts” means (i) the Amended and Restated Exclusive License Agreement between BeHealth and UVPF under
which BeHealth licenses Intellectual Property Rights and Critical Data rights related to SHUTi, and is in the form mutually agreed by Pear, BeHealth and UVPF, attached hereto as Exhibit F (the “Assigned UVPF License”), and
(ii) the research study agreements set forth in Exhibit B. 
 1.4. “Background IP” means all Intellectual Property
Rights owned or controlled by BeHealth related to SHUTi, including any improvements thereto owned or controlled by BeHealth, existing as of the Effective Date and/or otherwise generated or acquired by BeHealth outside of this Agreement after the
Effective Date and related to SHUTi, excluding the Assigned Assets. 

 1.5. “Change of Control Transaction” shall mean the consolidation or merger
of Pear with or into any other corporation, corporations, or other entities, or a sale, conveyance, or a sublicense of a majority of its rights and obligations under this Agreement to a third party, or disposition of all or substantially all of the
assets of Pear, or the effectuation by Pear of a transaction or series of transactions in which at least fifty percent (50%) of the voting power of Pear is disposed of. 

1.6. “Closing Date” means the date on which the latest of the following occurs: 

(i) BeHealth and UVPF execute the Assigned UVPF License, and (ii) either (A) BeHealth delivers the Critical Data and the ability for Pear to use the same
for purposes of regulatory filings and in promotional materials (which is through the Assigned UVPF License for the UVPF Critical Data component) to Pear under Section 3.4, or (B) Pear otherwise delivers its Notice of Non-Termination under Section 9.1(ii). 
 1.7. “Commercially Reasonable Efforts”
means that level of effort and resources that is customary in the medical device and therapeutic treatment industry for carrying out in a sustained manner a particular task or obligation to develop and commercialize a medical device or therapeutic
treatment solution, as the case may be, and in any event, not less than the same efforts typically expended by a company of similar size, stage of development and resources to carry out such task or to develop and commercialize the same, taking into
account (in the exercise of Pear’s reasonable business discretion), market potential, sales potential and strategic value, based on conditions then prevailing and reasonably expected to occur (it being understood that a delay or cessation of
efforts to achieve one or more Milestones may be consistent with Commercially Reasonable Efforts). 
 1.8.
“Confidential Information” means any confidential or proprietary information marked or identified as confidential or proprietary at the time of disclosure by the disclosing party, and including any source
code, software tools, designs, schematics, plans or any other information relating to any research project, work in process, future development, scientific, engineering, manufacturing, marketing or business plan or financial or personnel matter
relating to either party, its present or future products, services, customers, employees, investors or business. Without limiting the foregoing, and notwithstanding any marking or recordation requirement, from and after the Effective Date, the
Software and Documentation, and all Data delivered to Pear hereunder, shall, as between the parties, be deemed the Confidential Information, Data and Intellectual Property Rights of Pear. All Personal Information delivered to Pear hereunder shall be
deemed the Confidential Information of both parties. 
 1.9. “Critical Data” has the meaning set forth in Section 3.4.

 1.10. “Data” means data, including technical data, clinical data, user data, safety data rights in databases and data
collections (including knowledge databases, safety databases, user lists and user databases), in all cases owned by BeHealth and related to SHUTi (but excluding Personal Information). 

1.11. “Documentation” means any of BeHealth’s written operating procedures, methods, tools, developers’ kits,
utilities, developers’ notes, build scripts, test scripts, annotations, technical manuals, user manuals, planning materials on trials, clinical protocols, procedures for maintenance and modification, testing data, quality assurance reports,
post-launch issue tracking and update reports related to SHUTi, and all other BeHealth documentation and items embodying or describing SHUTi, the Software and related Know-How. 

 1.12. “Exploit” means to design, develop, make, have made, market, sell,
offer for sale, import, export, use, modify, make derivative works of, operate, distribute, license, transmit, display, commercialize, maintain and support. “Exploitation” means any or all of the activities to Exploit. 

1.13. “Gross Sales” means the gross amounts received by Pear, its subsidiaries and/or other Affiliates, its sublicensees,
and/or any other party that sells and/or subscribes SHUTi and/or Integrated Products (all calculations made in accordance with generally accepted accounting principles in the United States) for sales of and/or subscriptions to SHUTi and/or
Integrated Products to end users or entities purchasing on behalf of end users, less any normal and customary trade, quantity or cash discounts, amounts repaid or credited by reason of defects, rejections, recalls or returns (to the extent actually
incurred) and sales taxes, value-added taxes, excise or use taxes, tariffs, duties and customs fees and other taxes or governmental charges imposed by any governmental agency or authority (to the extent actually paid). Without limiting the
foregoing, Pear shall not structure any sale and/or subscription transaction for SHUTi and/or Integrated Products (or any Intellectual Property Rights related thereto) in such a manner as to avoid payment of any Milestones. Gross Sales will be
calculated only once with respect to each unit of SHUTi or Integrated Products sold or offered as subscriptions to third parties, even if such unit of SHUTi or Integrated Product is sold or offered more than once in the course of its transfer to the
ultimate end-user. For the avoidance of doubt, only the final sale or subscription to an end-user will be included in Gross Sales, and milestone payments made to Pear
from a sublicensee or commercialization partner shall not be included in Gross Sales. 
 1.14. “Integrated Product” means
any product or service that incorporates or relies on (in part or in whole) (i) SHUTi and/or the Software (including any Intellectual Property Rights included in the Assigned Assets), and/or (ii) Critical Data or other Data associated with
SHUTi and/or the Software. 
 Integrated Products may, by way of example only, include compliance software, medical support, and/or data
outcomes monitoring. 
 1.15. “Intellectual Property Rights” means all past, present, and future rights of the following
types, whether registered or unregistered, which may exist or be created under the laws of any jurisdiction in the world: (i) rights associated with works of authorship, including exclusive exploitation rights, copyrights, design rights, and
moral rights; (ii) trademark, trade name, service name, trade dress and service mark rights and similar means of identification and similar rights, including all goodwill associated with the foregoing; (iii) trade secret rights and other
rights in know-how and confidential or proprietary information (including any techniques, specifications, designs, processes, practical knowledge and skills, or other similar information) (collectively,
“Know-How”); (iv) United States and foreign patents, including utility models, industrial designs and design patents, and applications therefor (and any patents that issue as a result of those
patent applications), and any renewals, reissues, reexaminations, extensions, continuations, continuations-in-part, divisions and substitutions relating to any of such
patents and patent applications, and any counterparts worldwide claiming priority therefrom, and all rights in and to any of the foregoing (collectively, “Patents”); (v) all other intellectual property rights or proprietary rights,
and (vi) all past, present and future claims and causes of action arising out of or related to infringement or misappropriation of any of the foregoing. 

 1.16. “Net Sales” means the gross amounts received by Pear or its
Affiliates (all calculations made in accordance with generally accepted accounting principles in the United States) for sales of and/or subscriptions to SHUTi and/or Integrated Products to third parties, less [***] 

1.17. “Personal Information” means, collectively, (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank account information and other financial information, customer
or account numbers, account access codes and passwords, or any other piece of information that, alone or in combination with other information collected, held or otherwise managed by a party hereto, allows the identification of such natural person
or enables access to such person’s financial information; and (ii) any information relating to an identified natural person or a natural person who can be identified, directly or indirectly, in particular by reference to an identifier such
as a name, an identification number, location data, online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that person. Any information created or processed by a
party hereto that is based on Personal Information shall also be Personal Information. 
 1.18. “Regulatory Approvals”
means, with respect to SHUTi, all approvals, licenses, permits, registrations and authorizations from a governmental entity (including the U.S. Food and Drug Administration (“FDA”)) necessary for the Exploitation of SHUTi and any
Integrated Products in any country or territory, and all submissions, filings, reports and other documentation related to the foregoing. 

1.19. “SHUTi” means the digital therapeutic solution for insomnia licensed from UVPF under the Assigned UVPF License. 

1.20. “SHUTi Logo” means the logo design(s) and artwork owned by BeHealth related to SHUTi, and all Intellectual Property
Rights therein, excluding literal elements of trademark(s) incorporated therein to the extent not owned by BeHealth. 
 1.21.
“Software” means certain proprietary software owned by BeHealth and developed specifically for or used exclusively with SHUTi, including any files, processes, APIs, user interfaces, command structures, menus, buttons and icons,
flow-charts, firmware, codecs, and software implementations of algorithms, subroutines, models and methodologies owned by BeHealth and developed specifically for or used exclusively with SHUTi, whether in Source Code or Object Code or any other
form, as well as all App Store permissions and similar approvals relating to the commercialization thereof. “Object Code” means computer programming code in a form not readily perceivable by humans that is suitable for machine
execution, and “Source Code” means computer programming code in human readable form that is not suitable for machine execution without the intervening steps of interpretation or compilation. 

1.22. “UVPF” means the University of Virginia Patent Foundation. 

1.23. “UVPF Agreement” means the BeHealth Solutions LLC/UVPF License Agreement of April 1, 2011 (as amended), by and
between BeHealth and UVPF. 

 2. Assignment. Upon the terms and conditions set forth herein (including without limitation
Section 16.6), effective as of the Closing Date, BeHealth hereby sells, assigns, transfers and conveys to Pear, and Pear hereby accepts and acquires, all of BeHealth’s right, title and interest in and to the Assigned Assets. 

3. Delivery; Assistance. 
 3.1. In
General. BeHealth shall promptly (subject to the following sentence), deliver to Pear (i) all human-readable Source Code for the current commercial version of SHUTi in its possession and the Software, (ii) a copy of the
machine-executable Object Code for the current commercial version of for SHUTi in its possession and the Software, (iii) Data in BeHealth’s possession related to SHUTi or the Software (subject to Section 3.4 below), (iv) all Personal
Information in BeHealth’s possession related to SHUTi or the Software that BeHealth has the right to transfer to Pear (it being understood by Pear that BeHealth does not own such Personal Information) and (v) all Documentation in
BeHealth’s possession embodying or relating to SHUTi, the Software, and Know-How owned by BeHealth related to the foregoing (subject to Section 3.4 below). BeHealth shall deliver
(x) substantially all of the materials described in clauses (i) and (ii) of the foregoing sentence within ten (10) business days after the Effective Date, (y) substantially all of the materials described in clauses (iii) –
(v) of the foregoing sentence within ten (10) business days after the Closing Date, and (z) all of such materials within twenty (20) business days after the Closing Date. BeHealth shall provide Pear, its successors, assigns or other
legal representatives, such cooperation and assistance (at Pear’s expense) as Pear may reasonably request (including the execution and delivery of any and all patent or copyright applications, affidavits, declarations, oaths, exhibits,
assignments, powers of attorney, letters to a governmental entity, or other documentation as may be reasonably required), to enable Pear to perfect and sustain its rights in and to the Assigned Assets in accordance with the terms and conditions of
this Agreement. 
 3.2. UVPF Agreement. The Assigned Assets include BeHealth’s rights and obligations under the Assigned
Contracts. Pear hereby agrees to accept such assignment of rights and obligations upon the Closing Date in accordance with the foregoing and acknowledges and agrees it is bound by the terms and conditions of the Assigned Contracts from the Closing
Date (subject to Section 16.6). For purposes of clarity, from the Closing Date forward, Pear will either fulfill BeHealth’s clinical study support obligations pertaining to the clinical studies described in Exhibit B, or provide
appropriate support under the Consulting Agreement to enable BeHealth to fulfill such obligations. 
 3.3. Reserved.

 3.4. Data. Beginning on the Effective Date of this Agreement, BeHealth shall use best efforts to secure authorization within
ninety (90) days after the Effective Date to provide (or cause to be provided) to Pear the following Data related to SHUTi and the Software (i) as set forth on Exhibit A(i) attached hereto, which arose by virtue of a study
conducted with the University of Virginia under a grant titled “An Internet Intervention for Insomnia: Efficacy and Dissemination,” and (ii) as set forth on Exhibit A(ii) attached hereto, which arose by virtue of
a study conducted with the Australian National University (“ANU”) under a grant titled “A novel intervention targeting insomnia to prevent Major Depressive Disorder in the community” (such Data under clauses
(i) and (ii), collectively, “Critical Data”). Upon obtaining such authorization with respect to either of the foregoing studies, BeHealth will deliver (or cause to be delivered)

 
the applicable Critical Data within ten (10) days. If BeHealth is unable to secure such authorization with respect to either of the foregoing studies, BeHealth hereby consents to and shall
reasonably cooperate with Pear’s attempts to obtain such Critical Data directly from the educational institution. In addition, to the extent BeHealth has the requisite employees to support, BeHealth agrees to otherwise introduce Pear to
partners involved in any other research or clinical studies, partially or fully completed, involving BeHealth and related to SHUTi or the Software, and at Pear’s request, BeHealth will use reasonable efforts to assist Pear in obtaining Data
from other research or clinical studies relating to SHUTi or the Software and involving BeHealth. 
 4. Liabilities Not to be Assumed. Pear is not
assuming any debts, liabilities, obligations or contracts of BeHealth (other than the Assigned Contracts solely from and after the Closing Date) and all such excluded debts, liabilities, obligations and contracts shall be and remain the
responsibility of BeHealth. Without limiting the foregoing, Pear is not assuming and BeHealth shall not be deemed to have transferred to Pear any liability or obligation of BeHealth (i) arising out of or resulting from any product distributed
prior to the Closing Date or under Sections 5.2 or 5.3 (including any liability or obligation of BeHealth for claims made for infringement of intellectual property or other proprietary rights, injury to person, damage to property or other damage,
whether made in product liability, tort, breach of warranty or otherwise), (ii) arising out of any suits, actions, claims or proceedings of BeHealth, except as expressly set forth in Section 14, (iii) for any breach or failure to perform any of
BeHealth’s covenants and agreements contained in, or made pursuant to, this Agreement, or, prior to the Closing Date, the Assigned Contracts or any other contract, and (iv) for any violation of or failure to comply with any Law, order,
writ, injunction or decree of any court or governmental authority. 
 5. License Grants. 

5.1. From BeHealth. Subject to the terms and conditions of this Agreement (including without limitation Section 16.6), beginning on
the Closing Date, BeHealth hereby grants Pear a limited, non-exclusive, non-transferable (except as set forth in Section 17.6), , worldwide, Royalty-bearing (solely
as set forth in Section 9.3) license, with the right of sublicense (through multiple tiers), under and to BeHealth’s Background IP, to Exploit the Assigned Assets and any related Integrated Products for any indication and in any field of
use, including for drug/software combinations made part of Integrated Products as part of Pear or Pear-licensee prescription digital therapeutics applications. BeHealth acknowledges and agrees that Pear is under no obligation to mark or brand the
Software or any Integrated Product with any trademark, tradename, service mark, service name or other indicia of origin of BeHealth; provided, however, that to the extent Pear does so all goodwill arising therefrom shall inure to BeHealth’s
benefit and BeHealth shall have no liability with respect to any such rights. 
  

	 	5.1.1. 	 Interim License Grant. Subject to the terms and conditions of this Agreement, beginning on the Effective
Date and terminating on the Closing Date, BeHealth hereby grants Pear a limited, non-exclusive, non-transferable (except as set forth in Section 17.6), worldwide,
royalty-free (i) sublicense, under BeHealth’s rights in the UVPF Agreement, and (ii) license, under and to the Assigned Assets (excluding the Assigned Contracts) and BeHealth’s Background IP, to engage in development activities
related to SHUTi and the Software, and for purposes of developing, and/or submitting regulatory filings relating to, Integrated Products for any indication and in any field of 

	 	
use, including for drug/software combinations made part of Integrated Products as part of Pear or Pear-licensee prescription digital therapeutics applications. BeHealth acknowledges and agrees
that Pear is under no obligation to mark or brand the Software or any Integrated Product with any trademark, tradename, service mark, service name or other indicia of origin of BeHealth; provided, however, that to the extent Pear does so all
goodwill arising therefrom shall inure to BeHealth’s benefit and BeHealth shall have no liability with respect to any such rights. To the extent that, between the Effective Date and the Closing Date, Pear makes use of any rights in the Assigned
Assets not licensed to Pear under this Section 5.1.1, Pear acknowledges and agrees that such actions are solely at Pear’s risk and Pear shall be responsible for any liabilities caused by such actions. 

5.2. From Pear—Transitional. Subject to the terms and conditions of this Agreement, beginning on the Closing Date, Pear hereby
grants BeHealth a limited, co-exclusive (with Pear and without right of accounting), non-transferable (except as set forth in Section 17.6), fully paid-up and royalty-free license under the Assigned Assets to (i) use, license and distribute SHUTi as needed to service and support customers who purchase a subscription to SHUTi in a non-prescription form prior to the date that is thirty (30) days after Pear files a pre-submission briefing document with the FDA (the “Non-Prescription Sales Termination Date”) until all such subscriptions have expired, but in no event later than twelve (12) months after the Non-Prescription
Sales Termination Date; and (ii) provide general technical support, site hosting services and related services to SHUTi research customers existing as of the Closing Date until such customers’ respective research studies end. 

5.3. From Pear – Freedom to Operate. Subject to the terms and conditions of this Agreement, beginning on the Closing Date, Pear
hereby grants BeHealth a limited, non-exclusive, non-transferable (except as set forth in Section 17.6), non-sublicensable,
fully paid-up and royalty-free, worldwide license under and to the Software and any improvements Pear makes to the Background IP, and the Intellectual Property Rights in the foregoing, to develop and
commercialize digital therapeutics. 
 5.4. Ownership. As between the parties, BeHealth shall continue to own all right, title and
interest in and to its Background IP, subject to the license granted to Pear under Section 5.1. As between the parties, Pear shall own all right, title and interest in and to the Assigned Assets from and after the Closing Date and to any works
Pear creates, including any modifications or derivative works of Assigned Assets or Background IP, subject to the license granted to BeHealth under Section 5.3 and subject to Section 16.6.4. Without limiting the foregoing, BeHealth
acknowledges and agrees that as between the parties, Pear shall own all right, title and interest in and to its Integrated Products, all Data generated by or from Pear users’, and all clinical studies involving Pear resources. All rights not
expressly granted by either party hereunder are reserved. Each party agrees to execute such documents as are reasonably requested by the other party hereto to give effect to this Section 5.4. 

6. Commercialization Efforts. Beginning on the Closing Date, Pear agrees to use (and, to the extent applicable, shall cause its Affiliates and
sublicensees to use) Commercially Reasonable Efforts to (i) pursue the further development and commercialization of SHUTi and/or Integrated Products, (ii) obtain marketing clearance from the US FDA for SHUTi and/or an Integrated Product,
and (iii) commercialize SHUTi and/or an Integrated Product. Pear’s achievement, by itself or 

 
through its Affiliates or sublicensees, of the Milestones in Section 9.2 of this Agreement with respect to SHUTi and/or an Integrated Product shall be deemed sufficient to satisfy the
requirement to use Commercially Reasonable Efforts under (i), (ii) and (iii) above, provided that, except for Pear’s obligation to exercise Commercially Reasonable Efforts as set forth in this Section 6, the parties acknowledge Pear
shall have no obligation to actually achieve any Milestone. If Pear (x) fails to exercise Commercially Reasonable Efforts in accordance with this Section 6, and/or (y) fails to file an application for marketing clearance for the sale
of SHUTi or an Integrated Product with the FDA within eighteen (18) months of the Closing Date (such eighteen months to be extended on a day-for-day basis to
reflect delays in the FDA process that are not attributable to the action or inaction of Pear, including delays caused by the FDA’s failure to comply with statutory timelines pertaining to responses, decisions and meeting requests, or if the
FDA requests SHUTi-related data that is not within the Critical Data; provided that Pear will notify BeHealth promptly of the occurrence of any such delay unless such notification would violate applicable Law), then in each case BeHealth has
the right (but not the obligation) to terminate this Agreement pursuant to Section 16.2 for Pear’s material uncured breach; provided, however, that in either case Pear, if Pear makes payment to BeHealth in the amount of [***] prior to the
end of the thirty (30) day cure period in Section 16.2, then the deadline set forth above in (y) shall be extended by an additional quarter. Pear shall have the right to extend the deadline contemplated herein for up to an additional
three (3) quarters thereafter upon an additional payment of [***] for each additional quarter extension. Any further deadline extensions are subject to the mutual written agreement of both parties. During the Term of this Agreement from and
after the Closing Date (contemporaneously with Pear’s delivery of commercialization summary reports to UVPF but in no event less than semi-annually during the Term), Pear shall provide BeHealth status reports summarizing Pear’s (or its
Affiliates’ or sublicensees’, as applicable) efforts related to the further development of, Regulatory Approvals for and commercialization of, SHUTi and/or any Integrated Products, which reports shall be deemed Pear’s Confidential
Information. 
 BeHealth will cease any commercial sales activity of the SHUTi product as of the
“Non-Prescription Sales Termination Date”, including withdrawal of any publicly-available marketing or physician educations materials. BeHealth will transition any commercial users (but not
users in clinical trials) using the SHUTi product as of that date to an Expanded Access Program to be organized by Pear. 
 7. Clinical Trials.
Exhibit B identifies and sets forth the research studies supported by BeHealth that are using or plan to use SHUTi or the Software as of the Effective Date. 

8. Continuing Commercialization Assistance from BeHealth.    BeHealth agrees to provide Pear, at no additional expense to Pear, a
reasonable amount of qualified personnel time, not to exceed ten (10) hours per week for a maximum number of twelve (12) weeks after the Closing Date], reasonable access to BeHealth systems and facilities necessary to assist with the
Assigned Assets, as well as to assist Pear in the development and other Exploitation of the Assigned Assets. 
 In addition to the foregoing, BeHealth
shall, though qualified personnel, perform certain consulting services related to the Assigned Assets (including without limitation by making reasonably available Dr. Frances Thorndike (“Dr. Thorndike”) to perform certain of those
services) pursuant to a consulting agreement in the form attached hereto as Exhibit C (the “Consulting Agreement”); provided, however, that nothing herein guarantees Dr. Thorndike will be so
available.     

 For any other such individual requests, BeHealth shall consider in good faith such request and respond to
Pear based on the costs involved, contractual obligations and other business factors. Any requested services and/or support outside of the Consulting Agreement shall be subject to separate mutual written agreement of the parties. At any time on or
after the Closing Date, and otherwise provided that Pear is in material compliance with the terms and conditions of this Agreement, at Pear’s written request, BeHealth agrees to waive any requirements and/or agreements that would prevent Pear
from hiring Dr. Thorndike as a full-time employee of Pear; provided, however, that nothing herein obligates Dr. Thorndike to agree to any such employment. 

9. Payment. 
 9.1. Initial
Payments. Within five (5) days after the Closing Date, Pear shall pay BeHealth [***] (the “Initial Fee”) as consideration for meeting BeHealth’s delivery obligations with respect to Critical Data and as
consideration for BeHealth’s assistance in securing an assignment of the Assigned Assets. 
 In the event BeHealth for any reason fails to obtain
authorization to deliver to Pear any Critical Data within ninety (90) days after the Effective Date, Pear has ten (10) business days therefrom to provide BeHealth with written notice that either (i) Pear is terminating this Agreement,
and in such event BeHealth shall refund the Initial Fee (if paid) within sixty (60) days after such effective date of termination, or (ii) Pear is electing not to terminate this Agreement, in which case this Agreement shall continue and
BeHealth will have an additional sixty (60) days from the date of Pear’s notice to obtain authorization to deliver the remaining Critical Data. If after such sixty- (60-) day period, BeHealth for any
reason has failed to deliver to Pear such authorization to use Critical Data, and delivered the Critical Data, Pear has ten (10) business days therefrom to provide BeHealth with written notice that either (i) Pear is terminating this
Agreement, and in such event Pear shall not be required to pay the Initial Fee, or (ii) Pear is electing not to terminate this Agreement (the “Notice of Non-Termination”), in which case:
this Agreement shall continue; the Initial Fee is due in full and no refund of any amounts shall be required; and all other payments due and accruing under this Agreement shall otherwise apply. 

9.2. Milestone Payments. From and after the Closing Date, Pear agrees to pay BeHealth the corresponding
non-creditable, non-refundable amounts set forth below within sixty (60) days after the occurrence of each of the following events (“Milestones”):
Within five (5) days after the Closing Date, the Parties will have established an escrow account in the amount of [***] of the milestone amounts, intended to cover the totality of the second Regulatory Milestone and the first [***] of the first
Sales Milestone. Pear will contribute the escrow amount within five (5) days after the Closing Date. Fifty percent (50%) of the costs associated with escrow will be paid by BeHealth, and the other fifty percent (50%) will be paid by BeHealth.
Any breach of the foregoing escrow obligation constitutes a material breach of this Agreement. 

					
	 Milestone
	  	Payment	 
	 Regulatory Milestones
	  

	 FDA acceptance of a filing for marketing clearance for sale of SHUTi or an Integrated
Product
	  	$	750,000	 
	 Receipt by Pear of FDA marketing clearance/approval for SHUTi or an Integrated Product
	  	$	750,000	 
	 Sales Milestones
	  

	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 

 For purposes of clarity, each Milestone set forth above may only be achieved one time, and any associated payment amount in
connection with the achievement of any such Milestone will be payable only one time. Notwithstanding anything to the contrary set forth in this Agreement, in no event will any Milestone payment become due and payable after the date that is the 10th year anniversary of the Effective Date. Upon the individual and separate occurrence of each of the two Regulatory Milestones and the first Sales Milestone, BeHealth shall have the option to receive
the value of the Milestone payment otherwise payable in respect of such Milestone in the form of one or more warrants to purchase stock rather than cash, which warrant or warrants shall be substantially in the form attached hereto as Exhibit
D; provided that in the event BeHealth elects to receive such a warrant in lieu of cash for the second Regulatory Milestone and/or the first Sales Milestone, the corresponding monetary amounts that are in escrow shall be returned to Pear.
Upon notice to Pear of such election to receive a Milestone payment in warrants to purchase stock, Pear shall issue BeHealth a warrant to purchase that number of shares of company common stock determined pursuant to the applicable footnote of the
form of warrant attached as Exhibit D. The exercise price for each warrant shall be 0.01 per share. 
 9.3. Royalty Payments.
In addition to the payments above, starting on the first commercial sale and/or license of SHUTi or an Integrated Product (i.e., regardless of how structured/characterized by Pear) by or on behalf of Pear or its Affiliates (directly or indirectly
through third parties), on a country-by-country basis, and continuing until the later of (i) ten years thereafter in such country, or (ii) expiration of
regulatory exclusivity for SHUTi or the applicable Integrated Product in such country, Pear will pay to BeHealth a royalty of [***] of Net Sales in such country (the “Royalty”). Payments of Royalties will be made within sixty
(60) days following the end of each calendar quarter and will be accompanied by a report prepared and certified by Pear detailing the basis for the calculation of the payments due. Royalties will be
non-creditable and non-refundable (other than as set forth in Sections 9.1 and 16.6.4). All payments will be made in U.S. Dollars. 

9.4. Reimbursements. In connection with BeHealth’s assistance to Pear arising pursuant to the first sentence of Section 8,
Pear agrees to reimburse BeHealth’s actual expenses approved in writing in advance by Pear regarding any in-process clinical trials for SHUTi that are actually incurred by BeHealth after the Effective
Date. 

 9.5. Taxes. Pear shall be responsible for and shall pay any applicable,
separately-itemized sales, use, excise or similar taxes relating to the licensing or sale of SHUTi or Integrated Products, excluding any taxes based on BeHealth’s income. In the event Pear is required to withhold taxes imposed upon BeHealth for
any payment under this Agreement by virtue of the statutes, laws, codes or governmental regulations of any country, then such payments will be made by Pear on behalf of BeHealth by deducting them from the payment then due BeHealth and remitting such
taxes to the proper authorities on a timely basis, provided that Pear provides BeHealth with official documentation and/or tax receipts on such withholdings supporting such taxes and such payments as may reasonably be required by BeHealth for its
tax records. 
 9.6. Late Payments. Any Milestone payments, Royalty payments or payments due under the Consulting Agreement (or any
portion thereof) which are not paid when due, and which are not subject to dispute, shall bear interest equal to the prime rate as reported by the Chase Manhattan Bank, New York, New York, on the date such payment is due, plus an additional two
percent (2%), calculated based on the number of days such payment is delinquent. This Section 9.6 shall not limit other remedies available to BeHealth under this Agreement. BeHealth, from time to time upon reasonable notice to Pear and at
BeHealth’s expense as set forth herein, may appoint an independent auditor reasonably satisfactory to Pear to audit and verify the accuracy of Pear’s reports and payments hereunder. Such request for an audit shall not occur more than once
every twelve (12) months. The auditor and its authorized agents and representatives shall have access to inspect and copy books and records for purposes of such audit during normal business hours; provided, however, that if such audit discloses
that an error of five percent (5%) or more regarding invoices during the audited period was made in favor of Pear, then Pear shall (i) immediately remit payment in full to BeHealth accordingly, and (ii) pay the entire cost of such audit.

 10. Representations and Warranties. BeHealth represents and warrants to Pear, as of (i) with respect to Sections 10.1 and 10.2, the Effective
Date, and (ii) with respect to Sections 10.3 – 10.11, the Closing Date, as follows: 
 10.1. Authority. BeHealth has all
requisite power and authority to execute and deliver this Agreement and any and all instruments necessary or appropriate in order to perform its obligations under this Agreement existing as of the Effective Date or the Closing Date, as applicable.
This Agreement has been duly authorized, executed and delivered by all necessary action on the part of BeHealth and constitutes a valid and legally binding obligation of BeHealth. 

10.2. Non-Contravention. Subject to the following sentence, the execution, delivery and
performance of this Agreement does not and will not (i) conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both), or give rise to a right of, or result in, termination, cancelation or
acceleration of any obligation or to a loss of a benefit, or result in the creation of any lien, security interest or other encumbrance in or upon any of the Assigned Assets, or give rise to any increased, additional, accelerated or guaranteed
rights or entitlements, under any provision of any agreement to which BeHealth is a party or any Law or judgment, order or decree, or (ii) require any consent, approval, authorization or permit of, or filing by BeHealth with or notification by
BeHealth to, any government entity or any other person or entity. Notwithstanding Section 10 above, with respect to the Assigned Contracts only, BeHealth makes the foregoing representation and warranty as of the Closing Date instead of the
Effective Date. 

 10.3. Registered IP. To BeHealth’s knowledge, Exhibit E contains a
complete and accurate list of all registered Intellectual Property Rights related to SHUTi (“Registered IP”). BeHealth acknowledges it owns no applications or registrations for Intellectual Property Rights related to the Software.
BeHealth has not received any written communication or notice relating to any opposition, cancelation or similar proceeding with respect to any Registered IP or the Software, or to any claim or allegation concerning the validity or ownership of any
Registered IP or the Software. To BeHealth’s knowledge, the Registered IP is valid and subsisting. BeHealth does not own the Registered IP. 

10.4. Title. BeHealth exclusively owns all right, title and interest in and to the Assigned Assets (for the avoidance of doubt,
excluding Intellectual Property Rights and Data licensed to BeHealth under the Assigned Contracts and any research study Data owned and provided by third parties, including without limitation the Critical Data) free and clear of any encumbrances,
security interests, notes, loans, instruments, liens, judgments, orders, decrees, commitments, liabilities, licenses, agreements or other binding arrangements or obligations concerning the Assigned Assets between BeHealth and any other person or
entity. As of the Effective Date, BeHealth shall have the right to convey the Assigned Assets (for the avoidance of doubt, excluding Intellectual Property Rights and Data licensed to BeHealth under the Assigned Contracts and any research study Data
owned and provided by third parties, including without limitation the Critical Data) to Pear. 
 10.5. Sufficiency. On or prior to
the Closing Date, BeHealth will deliver to Pear a complete and accurate list of the computer software modules and chapters that comprises the Software, together with all relevant Documentation. The Assigned Assets together with the rights licensed
to Pear pursuant to Section 5.1 constitute all of the Intellectual Property Rights used in or necessary for the Exploitation of the Software as performed as of the Effective Date. 

10.6. No Infringement. None of the Intellectual Property Rights and Data included in the Assigned Assets (excluding the Intellectual
Property Rights and Data licensed under the Assigned Contracts and any other Critical Data), and to BeHealth’s knowledge, none of the Intellectual Property Rights and Data licensed under the Assigned Contracts or any other Critical Data,
infringe, misappropriate or violate any Intellectual Property Right of any person or entity. 
 10.7. Open Source. To BeHealth’s
knowledge, there is no software or other materials included in, or distributed with, the Software, which are subject to, or could subject the Software to, the terms of a “free software,” “open source,” “copyleft” or
similar licensing or distribution terms, including but not limited to the GNU Public License, Mozilla Public License or BSD Licenses (“Open Source Materials”) in such a way that creates, or purports to create restrictions,
limitations or conditions on the right or ability to Exploit SHUTi or the Software. 
 10.8. Data and Privacy. BeHealth is and
has been in compliance with applicable Laws, contracts and privacy policies pertaining to its SHUTi users and their Personal Information to which BeHealth is subject (the “Privacy Agreements”). Neither the execution, delivery
or performance of this Agreement, nor the consummation of any of the transactions contemplated by this Agreement, will result in any violation of any Privacy Agreements. 

10.9. Accuracy of Data. BeHealth has not withheld from Pear, and will not withhold from Pear after the Effective Date to the extent it
becomes aware of, any unfavorable Data or results of any pre-clinical or clinical studies of any Assigned Assets. 

 10.10. Compliance with Laws. BeHealth, and all of BeHealth’s employees,
officers, independent contractors, consultants, or agents who have rendered services relating to the Assigned Assets, have complied with all applicable statutes, laws, ordinances, codes, rules or regulations (collectively, “Laws”)
relating to the creation, ownership and use of the Assigned Assets; and there are no claims, actions, lawsuits, complaints or other proceedings pending, or to BeHealth’s knowledge threatened, by any governmental entity with respect to any
alleged violation by BeHealth of any Law relating to the Assigned Assets. In particular, neither BeHealth, nor any of BeHealth’s employees, officers, independent contractors, consultants, or agents who have rendered services relating to the
Assigned Assets: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a (or its equivalent under applicable laws, rules or regulations); or
(ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a (or its equivalent under applicable laws, rules or regulations). 

10.11. Regulatory Approvals. BeHealth has not submitted (and has no knowledge of any third party having submitted), to any governmental
entities in any jurisdictions, and does not own or have any rights to, any Regulatory Approvals with respect to the Assigned Assets. 
 11. Non-compete. Subject to Pear’s material compliance with the terms and conditions of this Agreement and to closing this Agreement in accordance with Sections 1.6 and 9.1, (i) for a period of five
(5) years following the Effective Date, neither BeHealth nor Joe Jennings will, and (ii) for a period of two (2) years following the Effective Date, Dr. Thorndike will not, directly or indirectly, promote, market, sell or offer
to sell, license, distribute or otherwise commercialize any digital therapeutic in the field of insomnia (including insomnia with comorbid conditions such as depression), unless Pear consents in writing on a case-by-case basis. For clarity, general research in the field of insomnia, with or without comorbidities, does not violate the foregoing restrictions. 

12. Pear Covenant. Pear covenants and agrees that, from and after the Closing Date, Pear will use, store, disclose and otherwise treat Personal
Information provided by BeHealth under this Agreement in accordance with all applicable Privacy Agreements identified by BeHealth (other than Laws, which BeHealth shall not be required to identify) and all applicable Laws. 

13. Confidentiality. 
 13.1.
Nondisclosure. The parties acknowledge and agree that the Reciprocal Agreement for Disclosure of Confidential Information entered into by the parties effective November 2, 2017 (the “Prior NDA”) is hereby superseded and
replaced as of the Effective Date with the provisions of this Section 13, which shall govern the parties’ exchange of all Confidential Information from and after the Effective Date. All Confidential Information exchanged between the
parties pursuant to this Agreement shall not be distributed, disclosed, or disseminated by the receiving party to anyone except its own employees, agents or subcontractors who have a reasonable need to know such Confidential Information and who have
been advised of the confidential nature and required to observe the terms and conditions hereof; nor shall Confidential Information be used by the receiving party for its own purpose, except for the purposes of exercising its rights or fulfilling
its obligations under this Agreement. The restriction on disclosure will not apply to Confidential Information that is required to be disclosed by a court, government agency or regulatory requirement, provided that the recipient shall first notify
the disclosing party of such disclosure requirement or order and use reasonable efforts to obtain confidential treatment or a protective order. Without limiting the foregoing, each of the parties agrees not to make any announcement or other
disclosure regarding this Agreement or the activities contemplated hereby prior to the Closing Date without the other party’s prior written consent. 

 13.2. Exclusions. The obligations of Section 13.1 shall not apply to any
information that: 
  

	 	13.2.1.	 is already in the public domain or becomes available to the public through no breach of this Agreement or other
confidentiality obligation by the receiving party; or 

  

	 	13.2.2.	 was in the receiving party’s possession prior to receipt from the disclosing party as proven by the
receiving party’s written records; or 

  

	 	13.2.3.	 is received independently on a non-confidential basis from a third
party free to disclose such information to the receiving party; or 

  

	 	13.2.4.	 is derived independently by a receiving party without use of or reference to the disclosing party’s
Confidential Information or Intellectual Property Rights. 

 14. Indemnification. BeHealth shall indemnify, defend and hold Pear
harmless from and against any and all liabilities, losses, damages, costs and expenses, including reasonable attorneys’ fees arising out of any action, claim, suit or proceeding brought against Pear or Pear’s directors, officers,
Affiliates, sublicensees and/or customers based on (i) an allegation that any of the Assigned Assets infringes or misappropriates any Intellectual Property Rights of a third party (for the avoidance of doubt, excluding Intellectual Property
Rights and Data licensed to BeHealth under the Assigned Contracts), or (ii) a breach by BeHealth of any of its representations, warranties or covenants made under this Agreement. Pear shall indemnify, defend and hold BeHealth harmless from and
against any and all liabilities, losses, damages, costs and expenses, including reasonable attorneys’ fees arising out of any action, claim, suit or proceeding brought against BeHealth or BeHealth’s directors, officers, Affiliates,
sublicensees and/or customers based on a material breach by Pear of any of its representations, warranties or covenants made under this Agreement. 
 15.
Limitation of Liability. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT FOR EACH PARTY’S INDEMNITY OBLIGATIONS UNDER SECTION 14 OR ANY PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, NEITHER PARTY WILL BE
LIABLE FOR ANY LOSS OF USE, INTERRUPTION OF BUSINESS, LOST PROFITS, OR ANY INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING LOST PROFITS) REGARDLESS OF THE FORM OF ACTION WHETHER IN CONTRACT, TORT (INCLUDING
NEGLIGENCE), STRICT PRODUCT LIABILITY, OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, OTHER THAN IN CONNECTION WITH FRAUD, WILLFUL MISCONDUCT, EACH
PARTY’S INDEMNITY OBLIGATIONS UNDER SECTION 14 OR ANY PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, IN NO EVENT SHALL A PARTY’S LIABILITY UNDER THIS AGREEMENT EXCEED THE AMOUNTS PAID HEREUNDER. EACH PARTY ACKNOWLEDGES
THAT THIS LIMITATION OF LIABILITY IS AN ESSENTIAL ELEMENT OF THE BARGAIN BETWEEN THE PARTIES AND IN ITS ABSENCE, THE ECONOMIC TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY DIFFERENT. 

 16. Term; Termination Of Agreement. 

16.1. Term. This Agreement becomes effective on the Effective Date and shall continue in full force and effect until the expiration of
all Milestone and Royalty payment obligations hereunder unless terminated earlier as provided below. 
 16.2. Termination for Breach.
Either party may terminate this Agreement for cause by notice in writing if the other party shall at any time be in material breach of this Agreement and shall fail to remedy such breach (if capable of remedy) within thirty (30) days from
receipt of notice in writing from the first party specifying such breach. 
 16.3. Reserved. 

16.4. No Waiver of Termination. No failure or delay on the part of either party in exercising its right of termination hereunder for
any one or more causes shall be construed to prejudice its rights of termination for such cause or any other or subsequent cause. 
 16.5.
No Release. The termination of this Agreement shall not release either party from any liability which, at said date of termination, has already accrued to the other party. 

16.6. Effect of Termination.  
  

	 	16.6.1.	 By BeHealth For Cause. In the event that BeHealth terminates this Agreement for cause pursuant to
Section 6 and/or Section 16.2, then the license granted in Section 5.1 and the non-compete obligation under Section 11 shall automatically and immediately terminate and be of no further
effect and the provisions of Sections 16.6.4 and 16.6.5 shall otherwise apply. 

  

	 	16.6.2.	 By Pear For Cause. In the event Pear terminates this Agreement for cause pursuant to Section 16.2,
then the licenses granted in Section 5.2 and 5.3 shall automatically and immediately terminate and be of no further effect, the license granted in Section 5.1 shall survive, and the provisions of Section 16.6.5 shall otherwise apply.

  

	 	16.6.3.	 Reserved. 

 

	 	16.6.4.	 Reversion of Rights. Following termination of this Agreement by BeHealth pursuant to Section 6 or
Section 16.2 or by Pear pursuant to Section 9.1, Pear hereby does and shall assign back to BeHealth all of Pear’s right, title and interest in and to Assigned Assets and SHUTi. For the avoidance of doubt, Pear shall retain ownership
to any Intellectual Property Rights it holds outside of the Assigned Assets and SHUTi, including the elements of any Integrated Products outside of the foregoing. 

	 	16.6.5.	 Other Effects of Termination; Survival. Upon any expiration, Pear shall have no further obligation to
pay Royalty and Milestone payments specified in Section 9 (other than amounts due and payable prior to the effective date of expiration). Upon any sooner termination of this Agreement, Pear’s obligations to pay Royalty and Milestone
payments to BeHealth as specified in Section 9 continues, provided that beginning on the effective date of termination, all payment obligations set forth herein shall be reduced by ten percent (10%), except in the event Pear assigns back
the Assigned Assets and SHUTi to BeHealth in accordance with 16.6.4, in which case such payment obligations shall terminate as of the effective date of termination. For the avoidance of doubt, any continued use by Pear of the Assigned Assets and
SHUTi and/or the Background IP after termination requires payment of the Royalty and Milestone payments at a ten percent (10%) reduction.    Upon any expiration or sooner termination of this Agreement, each party shall return or
destroy any Confidential Information of the other party then in its possession. In addition to the foregoing, the following sections shall survive any termination or expiration of this Agreement: 1, 4, 5.4, 11 (except as set forth in
Section 16.6.1), 13, 14, 15, 16.5, 16.6 and 17. 

 17. MISCELLANEOUS. 

17.1. Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by each party are, and will otherwise be deemed to
be, for purposes of Section 365(n) of Title 11 of the United States Code (the “Bankruptcy Code”) and other similar foreign laws, licenses of right to “intellectual property” as defined under Section 101 of the
Bankruptcy Code or such foreign laws. The parties agree that either party, as a licensee, will retain and may fully exercise all of its rights and elections under applicable law and under the Bankruptcy Code. Each party agrees to notify the other
party hereto in the event of any insolvency or bankruptcy filing event that might affect the rights granted hereunder to allow the other party an opportunity to object to any transfer in bankruptcy that might lead to the rejection of any pre-existing licenses. Without limiting the foregoing, the parties agree that either party may assert without objection from the other party hereto that this Agreement is not vulnerable to rejection under the
Bankruptcy Code and that, if rejected, such rejection shall not result in termination of the Agreement or a similar result or effect. All rights, powers and remedies of each party provided herein are in addition to and not in substitution for any
and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a bankruptcy case. 

17.2. Waiver. No failure or delay by any party hereto in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial waiver thereof include any other or further exercise thereof or the exercise of any other right, power or privilege. 

17.3. Amendment. Unless otherwise provided herein, this Agreement may not be changed, waived, discharged, or terminated orally, but
only by a written document signed by duly authorized officers of each of the parties hereto. 
 17.4. Notices. All notices and other
communications required or permitted hereunder shall be in writing and shall be mailed by first-class, registered or certified mail, postage prepaid, or delivered either by hand or by messenger, or sent via telecopier, at the addresses first set
forth above or at such other address as each party shall have furnished to the other in writing. Any notice or other communications so provided shall be deemed to be given when actually received by the addressees. 

 17.5. Relationship of Parties. Nothing herein contained shall be deemed to create an
agency, joint venture or partnership relation between the parties hereto. It is understood and agreed that neither party is, by reason of this Agreement or anything herein contained, constituted or appointed the agent or representative of the other
party for any purpose whatsoever. 
 17.6. Assignment of Agreement. Neither party may assign this Agreement nor any of its rights or
obligations hereunder without the prior written consent of the other party, such consent not to be unreasonably conditioned, delayed or withheld. Notwithstanding the foregoing, upon advance written notice to the other party hereto, either party may
assign this Agreement and its rights and obligations hereunder to a successor in interest without the other party’s consent upon any merger, reorganization, acquisition, Change of Control Transaction, or sale of all or substantially all of the
assets of the assigning party provided such successor in interest assumes all of such party’s obligations under this Agreement. Any purported assignment not in compliance with this Section 17.6 shall be deemed null and void from the
beginning. This Agreement is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns. 

17.7. Governing Law. The rights and obligations of the parties under this Agreement shall not be governed by the provisions of the 1980
United Nations Convention on Contracts for the International Sale of Goods or the United Nations Convention on the Limitation Period in the International Sale of Goods, as amended; rather, these rights and obligations shall be governed in all
respects by the laws of New York, without regard to conflict of law provisions. 
 17.8. Severability. Whenever possible, each
provision of the Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of the Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of the Agreement. 
 17.9. Headings;
Construction. The headings to the clauses, sub-clauses and parts of this Agreement are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or
interpretation of this Agreement. The terms “this Agreement,” “hereof,” “hereunder” and any similar expressions refer to this Agreement and not to any particular Section or other portion hereof. The parties hereto agree
that any rule of construction to the effect that ambiguities are to be resolved against the drafting party will not be applied in the construction or interpretation of this Agreement. As used in this Agreement, the words “include” and
“including,” and variations thereof, will be deemed to be followed by the words “without limitation.” 
 17.10.
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

17.11. Entire Agreement. This Agreement, including all exhibits attached hereto and any and all Statements of Work issued hereunder,
constitute the entire agreement between the parties with respect to the subject matter hereof, and supersedes any prior agreements, or understandings of the parties hereto in either written or oral form. 

 IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the Effective Date set forth above. 
  

									
	BeHealth Solutions, LLC:	 		 	Pear Therapeutics, Inc.:
					
	By:	 	 /s/ Joseph L. Jennings
	 		 	By:	 	 /s/ Corey McCann

	Name:	 	Joseph L. Jennings	 		 	Name:	 	Corey McCann
	Title:	 	Chief Executive Officer	 		 	Title:	 	Chief Executive Officer

 EXHIBIT A 

Critical Data Components 
 The parties
acknowledge and agree that the following items comprise a complete set of each of the Critical Data sets contemplated under this Agreement: 
 A(i)
– UVPF Critical Data Set: 
 [***] 
 A(ii)
– ANU Critical Data Set: 
 [***] 

 EXHIBIT B 

Clinical Studies 
 Clinical Trial 1

 Institution: University of Kentucky 

Principal Investigator: Mairead Moloney, PhD 

Years of Research Grant: 2017-2018 

Grant Title: Evaluating Online Cognitive Behavioral Therapy to Reduce Stress, Insomnia, and Sedative Hypnotic Use in Appalachian Women Aged 45+

 Goal: To pilot test the feasibility, acceptability, and promise of online cognitive behavioral therapy for insomnia (CBT-I) in women ages 45+. 
 Trial responsibilities: BeHealth Solutions 

Status: Ongoing recruitment 

Estimated Completion Date: April 2018 

Clinical Trial 2 
 Institution:
Indiana University 
 Principal Investigators: Jesse Stewart, PhD and Samir K Gupta, MD, MS 

Years of Research Grant: 2017-2018 

Grant Title: Internet-Based Cognitive Behavioral Therapy to Treat Insomnia in HIV: A Pilot Trial 

Goal: The goal of this preliminary study is to determine the efficacy of an internet-based treatment program for insomnia for HIV-infected person 
 Trial responsibilities: BeHealth Solutions 

Status: Signed contract. Waiting to begin enrollment. 

Clinical Trials registry: 

https://clinicaltrials.gov/ct2/show/NCT03390114?term=CBT&cond=insomnia&draw=9&rank=81 

Estimated Completion Date: October 2019 

Clinical Trial 3 
 Institution:
University of Pittsburgh 
 Principal Investigator: Eileen R. Chasens 

Years of Research Grant: 2017-2020 

Grant Title: Self-Management, Insomnia, and Glucose Control in Adults with Diabetes 

Goal: This study will test the effect of an insomnia intervention with cognitive behavioral treatment delivered via web compared with an
information control group on glucose control and self management behavior in a sample of persons with type 2 diabetes (T2DM). 
 Trial
responsibilities: BeHealth Solutions 
 Status: Ongoing 

Clinical Trials registry: 

https://clinicaltrials.gov/ct2/show/NCT03064321?term=Eileen+R.+Chasens&rank=3 

Estimated Completion Date: July 2018 

Clinical Trial 4 
 Institution:
Canadian Institutes of Health Research 

 Principal Investigator: Charles Morin, PhD 

Years of Research Grant: 2016-2023 

Grant Title: Insomnia: Research Innovations to Optimize Treatment Outcome in Primary Care 

Trial responsibilities: BeHealth Solutions 

Status: Development (French translation) work ongoing. 

Estimated Completion Date: August 2018 

Clinical Trial 5 
 Institution:
University of Colorado, Denver; Veteran’s Health Administration 
 Principal Investigator: Sarra Nazem, PhD 

Years of Research Grant: 2017-2018 

Grant Title: Computerized Cognitive Behavioral Treatment for Insomnia: Improving Rural Veteran Access to Evidence-based Treatment to Reduce
Suicide Risk (R-Vets Sleep). 
 Goal: This randomized controlled trial will determine whether a
computerized, self-guided, web-based version of CBT-I is efficacious in reducing insomnia symptoms and improving functioning compared to a computerized program control.

 Trial responsibilities: BeHealth Solutions 

Status: Development ongoing. 

Clinical Trials registry: https://clinicaltrials.gov/ct2/show/NCT03365024?term=nazem&rank=3 

Estimated Completion Date: July 2020 

Clinical Trial 6 
 Institution:
University of Colorado, Denver; Military Suicide Research Consortium (MSRC) 
 Principal Investigator: Sarra Nazem, PhD 

Years of Research Grant: 2017-2020 

Grant Title: Efficacy of a Computerized Cognitive Behavioral Treatment for Insomnia: Increasing Access 

to Insomnia Treatment to Decrease Suicide Risk 

Goal: This randomized controlled trial will determine whether a computerized, self-guided, web-based

 version of CBT-I is efficacious in reducing insomnia symptoms and improving functioning compared
to a 
 computerized program control. 

Trial responsibilities: BeHealth Solutions 

Status: Development ongoing. 

Clinical Trials registry: https://clinicaltrials.gov/ct2/show/NCT03366870?term=nazem&rank=2 

Estimated Completion Date: March 2019 

Clinical Trial 7 
 Institution:
Veterans Health Administration 
 Principal Investigator: Eric Hermes, MD 

Years of Research Grant: 2017-2022 

Grant Title: Implementing and Evaluating Computer-Based Interventions for Mental Health: 

 
Testing an 
 Implementation Strategy for VA Outpatient Care 

Goal: The purpose this study is to evaluate the preliminary (1) effectiveness of an implementation 

strategy for Internet-based Self-help Interventions and (2) clinical outcomes of a specific Internet-based 

self-help program for insomnia, SHUTiTM, in VA Connecticut outpatient primary care. 

Trial responsibilities: BeHealth Solutions 

Status: Recruitment ongoing. 

Clinical Trials registry: 

https://clinicaltrials.gov/ct2/show/NCT03151083?term=hermes&draw=2&rank=11 

Estimated Completion Date: November 2018 

Clinical Trial 8 
 Institution:
Dana-Farber Cancer Institute 
 Principal Investigator: Eric Zhou, PhD 

Years of Research Grant: 2016—2020 

Grant Title: Web-Based Cognitive-Behavioral Treatment for Insomnia in Adolescent Cancer Survivors. 

Goal: The purpose of this study is to learn whether an adapted version of SHUTi (Sleep Healthy Using the Internet), a six-session online program which has been found to be effective in other groups of people, will be useful in treating insomnia in adolescent and young adult cancer survivors. 

Trial responsibilities: BeHealth Solutions 

Status: Development ongoing. 

Clinical Trials registry: https://clinicaltrials.gov/ct2/show/NCT03279055?term=eric+zhou&rank=1 

Estimated Completion Date: June 2019 

Clinical Trial 9 
 Institution:
Norwegian Institute of Public Health 
 Principal Investigator: Borge Sivertsen 

Years of Research Grant: 2015 – 2019 

Grant Title: Overcoming Insomnia. From Genes to Long-term Impact on Health and Work. A Large RCT of Online Cognitive-behavioral Therapy for
Insomnia. 
 Goal: To evaluate the short and long term efficacy of SHUTi using the biobank from the world’s largest health survey (the
HUNT3 in Norway). 
 Trial responsibilities: BeHealth Solutions 

Status: 24-month f/up data collection begins March 2018. 

Clinical Trials registry: 

https://clinicaltrials.gov/ct2/show/NCT02558647?term=CBT&cond=insomnia&draw=5&rank=40 

 EXHIBIT C 

CONSULTING AGREEMENT 

This Consulting Agreement (this “Agreement”) dated as of the Effective Date (as defined below) , is made by and
between Pear Therapeutics, Inc., a Delaware corporation with offices at 745 Atlantic Ave., Boston, MA 02111 (the “Company”), and BeHealth Solutions, LLC, a Virginia limited liability company with offices at 375 Greenbrier
Drive, Charlottesville, VA 22901 (the ”Consultant”). 
 WHEREAS, the Company has entered into an Assignment,
License & Services Agreement with Consultant (the “Main Agreement”) dated as of March 23, 2018 (the “Effective Date”), and terms not defined herein have the meaning set forth in the Main
Agreement; and 
 WHEREAS, in connection with the transactions contemplated in the Main Agreement, the Company desires to engage the
Consultant to perform consulting services for the Company and the Consultant desires to perform such services on the terms and conditions hereinafter set forth; 

NOW, THEREFORE, in consideration of the premises and the mutual covenants set forth herein the parties hereby agree as follows: 

1. Consulting Services. 

(a) The Company hereby retains the Consultant and the Consultant hereby agrees to perform such consulting and advisory services as the Company
may request, including those set forth in Schedule A and such other services as may be mutually agreed upon by Consultant and the Company from time to time (the “Consulting Services”). 

(b) The Consultant personnel described in Schedule A will be available to render the Consulting Services, at such times and
locations as the Company may reasonably request from time to time. The manner and means of the Consultant’s provision of Consulting Services hereunder shall be in the sole discretion of the Consultant. Except as provided in Schedule
A, the Consultant may deliver the Consulting Services over the internet, in person or by written correspondence. 
 (c) The
Consultant shall ensure its personnel complies with all rules, procedures and standards promulgated from time to time by the Company with regard to Consultant’s access to and use of the Company’s property, information, equipment and
facilities. 

 2. Compensation. The Company shall pay the Consultant a consulting fee as
provided in Schedule A. The Company will reimburse the Consultant for such reasonable travel and other expenses as are incurred by the Consultant in the performance of Consulting Services for the Company and pre-approved in writing by the Company. Consultant understands that no payment can be made until the Company receives a fully completed IRS Form W-9, a copy of which has been
provided. 
 3. Independent Contractor. In furnishing the Consulting Services, the Consultant understands that the Consultant
will at all times be acting as an independent contractor of the Company and, as such, neither the Consultant nor any of its personnel will be deemed an employee of the Company and will not by reason of this Agreement or by reason of the 

Consulting Services to the Company be entitled to participate in or to receive any benefit or right under any of the Company’s employee benefit or
welfare plans. The Consultant also will be responsible for paying all withholding and other taxes required by law to be paid as and when the same become due and payable. Consultant shall not enter into any agreements or incur any obligations on
behalf of the Company. 
 4. Term. This Agreement shall commence on the Effective Date and continue until the earlier of
(i) ninety (90) days after the Closing Date, or (ii) termination of the Main Agreement (the initial term); provided, however, that in the event of (i) occurring, this Agreement shall automatically renew for subsequent ninety
(90) days periods (each a renewal term, and together with the initial term, the “Term”) until such time as a party hereto provides the other party hereto with thirty (30) days advance written notice of its intent to
terminate this Agreement. Without limiting the foregoing, the Company may terminate this Agreement at any time for any reason, without cause and without prior notice upon thirty (30) days advance written notice. 

5. Exceptions to this Agreement. 

Certain other contracts. The Company acknowledges that the Consultant is now or may become a party to agreements with third
parties relating to the disclosure of information, the ownership of inventions, restrictions against competition and/or similar matters. The Consultant represents and agrees that the execution, delivery and performance of this Agreement does not and
will not conflict with any other agreement, policy or rule applicable to the Consultant. The Consultant will not (i) disclose to the Company any information that it is required to keep secret pursuant to an existing confidentiality agreement
with a third party, (ii) use the funding, resources, facilities or inventions of any third party to perform the Consulting Services, or (iii) perform the Consulting Services in any manner that would give any third party rights to any
intellectual property created in connection with such services. 

 6. Confidential Information. 

(a) During the term of this Agreement and thereafter, the Consultant shall not, directly or indirectly, use any Confidential Information (as
defined below) other than pursuant to its provision of the Consulting Services by and for the benefit of the Company, or disclose to anyone (including other personnel of the Consultant) any such Confidential Information. The term
“Confidential Information” as used throughout this Agreement shall mean all trade secrets, proprietary information and other data or information (and any tangible evidence, record or representation thereof), written or oral,
whether prepared, conceived or developed by a consultant or employee of the Company (including the Consultant) or received by the Company from an outside source, which is in the possession of the Company (whether or not the property of the Company)
and which is maintained in secrecy or confidence by the Company. Without limiting the generality of the foregoing, Confidential Information shall include 

 (i) any idea, improvement, invention, innovation, development, concept, technical data,
design, formula, device, pattern, sequence, method, process, composition of matter, computer program or software, source code, object code, algorithm, model, diagram, flow chart, product specification or design, plan for a new or revised product,
sample, compilation of information, or work in process, or parts thereof, and any and all revisions and improvements relating to any of the foregoing (in each case whether or not reduced to tangible form); and 

(ii) the name of any customer, supplier, employee, prospective customer, sales agent, supplier or consultant, any sales plan, marketing
material, plan or survey, business plan or opportunity, product or development plan or specification, business proposal, financial record, or business record or other record or information relating to the present or proposed business of the Company.

 Notwithstanding the foregoing, the term Confidential Information shall not apply to information (i) which the Company has
voluntarily disclosed to the public without restriction or which has otherwise lawfully entered the public domain without a breach of any confidentiality obligations, (ii) was independently developed by the receiving party through no use of or
access to the Confidential Information, or (iii) was obtained by the receiving party from a third party without any obligation of confidentiality. 

(b) The Consultant acknowledges that the Company from time to time has in its possession information (including product and development plans
and specifications) which represent information which is claimed by others to be proprietary and which the Company has agreed to keep confidential. The Consultant agrees that all such information shall be Confidential Information for purposes of
this Agreement. 
 (c) The Consultant agrees that all originals and all copies of materials containing, representing, evidencing, recording,
or constituting any Confidential Information, however and whenever produced (whether by the Consultant or others), shall be the sole property of the Company. 

(d) The Consultant acknowledges that any data that may come into the possession of the Consultant may be subject to federal and state laws,
rules and regulations relating to among other subjects, the confidentiality, privacy or security of patient information, including without limitation, the Administrative Simplification Provisions of the Health Insurance Portability and
Accountability Act of 1996, Public Law 104-191.45 C.F.R. Part 160, 162, 164 (“HIPAA”) and the applicable regulations promulgated thereunder. The Consultant will, and will require its
personnel to, at all times comply with the applicable provisions of such laws, rules, and regulations and with the applicable corporate policies and provision of the Company, with respect to the performance of obligations under this Agreement, with
respect to the confidentiality, privacy and security of Protected Health Information (“PHI”) and electronic Protected Health Information, as defined in 45 C.F.R. § 164.501 (“ePHI”). For purposes
of this Agreement, PHI means individually identifiable information as defined by the Standards for 

 Privacy of Individually Identifiable Health Information, 45 C.F.R. Parts 160 and 164. Any willful or grossly
negligent breach of confidentiality, willful or grossly negligent destruction of computer equipment or data, or knowing or grossly negligent violation of HIPAA, its implementing regulations, or any other federal or state law protecting the integrity
and confidentiality of PHI by the Consultant will be subject to punishment to the fullest extent permitted by law. The Consultant understands and acknowledges that a breach of this Section 6(d) may be
grounds for termination of this Agreement and/or imposition of penalties. The Company represents and warrants that it is in compliance with HIPAA and has the right to provide Consultant with any and all such data, PHI and ePHI supplied pursuant to
this Agreement as contemplated herein. 
 7. Inventions. 

(a) Certain inventions made by others. During the Term of this Agreement, to the extent the Consultant identifies technology and
product opportunities in the Field of Interest (as defined in Section 14(j)) that arise outside of this Agreement, the Consultant will use commercially reasonable efforts to work with the Company
thereon (subject to a separate written definitive agreement mutually agreed to by the parties). 
 (b) Inventions made by the
Consultant. The Consultant agrees that all (i) of the Company’s Confidential Information and (ii) subject to payment in full to Consultant as required in this Agreement, all other discoveries, inventions, ideas, concepts,
trademarks, service marks, logos, processes, products, formulas, computer programs or software, source codes, object codes, algorithms, machines, apparatuses, items of manufacture or composition of matter, or any new uses therefor or improvements
thereon, or any new designs or modifications or configurations of any kind, or works of authorship of any kind, including, without limitation, compilations and derivative works, whether or not patentable or copyrightable, conceived, developed,
reduced to practice or otherwise made by the Consultant, either alone or with others, in each case that arise out of the Consulting Services or the Company’s Confidential Information, whether or not conceived, developed, reduced to practice or
made on the Company’s premises (collectively “Inventions”), shall be the sole property of the Company and all copyrights, patents, patent rights, trademarks and reproduction rights to, and other proprietary rights in,
each such Invention or Company Confidential Information, whether or not patentable or copyrightable, shall belong exclusively to the Company without further compensation of any kind to Consultant. The Consultant agrees that all such Inventions shall
constitute works made for hire under the copyright laws of the United States and hereby assigns and, to the extent any such assignment cannot be made at the present time, agrees to assign to the Company (and will cause its personnel to assign to the
Company), without any additional consideration from the Company, any and all copyrights, patents and other proprietary rights he may have in any such Invention, together with the right to file and/or own wholly without restrictions applications for
United States and foreign patents, trademark registration and copyright registration and any patent, or trademark or copyright registration issuing thereon. 

 8. Indemnification. Consultant will defend, hold harmless, and
indemnify the Company, and/or its subsidiaries, affiliates, directors, officers, employees, agents, successors and assigns (collectively, “the Company Indemnified Parties”), from and against any allegation or claim based on,
or any loss, damage, settlement, cost, expense and any other liability (including but not limited to reasonable attorneys’ fees) (collectively, “Claims”), arising from or related to: (i) any act or omission by
Consultant and/or its personnel, including without limitation, any breach or alleged breach of any of its representations, warranties or obligations contained in this Agreement, or (ii) Consultant’s violation of any applicable law or
regulation in performing the Consulting Services under the Agreement. Consultant’s duty to defend is independent of its duty to indemnify. Consultant’s obligations under this section are independent of all of its other obligations under
this Agreement. The Company will defend, hold harmless, and indemnify the Consultant, and/or its subsidiaries, affiliates, directors, officers, employees, agents, successors and assigns (collectively, “the Consultant Indemnified
Parties”), from and against any Claims arising from or related to (i) any act or omission by the Company and/or its personnel, including without limitation, any breach or alleged breach of any of its representations, warranties or
obligations contained in this Agreement, or (ii) the Company’s violation of any applicable law or regulation, or (iii) any injury or death of a Consultant employee or representative while on site at the Company or its designated
locations. 
 9. Consultant’s Obligation to Keep Records. Consultant shall (and shall require its personnel to) make and
maintain adequate and current written records of all Inventions, and shall disclose all Inventions promptly, fully and in writing to the Company immediately upon development of the same and at any time upon request. 

10. Consultant’s Obligation to Cooperate. The Consultant will, at any time during or after the term of this Agreement, upon
request of the Company, execute all documents and perform all lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. Without limiting the generality of the
foregoing, the Consultant will, and will require its personnel to, at Company’s expense: (i) assist the Company in any reasonable manner to obtain for the Company’s benefit patents or copyrights in any and all countries with respect
to all Inventions assigned pursuant to Section 7, and the Consultant will, and will require its personnel to, execute, when requested, patent and other applications and assignments thereof to the
Company, or Persons (as defined in Section 14(j)) designated by it, and any other lawful documents deemed necessary by the Company to carry out the purposes of this Agreement; and (ii) assist the
Company in every way to enforce any patents and copyrights obtained, including testifying in any suit or proceeding involving any of said patents or copyrights or executing any documents deemed necessary by the Company. 

11. Authority. The Consultant hereby represents and warrants that it has the full power and authority to carry out its
obligations hereunder. 
 12. [Omitted] 

13. Return of Property. Upon termination of the Consultant’s engagement with the Company, or at any other time upon request
of the Company, the Consultant shall, and shall require its personnel to, return promptly any and all Confidential Information, including customer or prospective customer lists, other customer or prospective customer information or related
materials, computer programs, software, electronic data, specifications, drawings, blueprints, medical devices, samples, reproductions, sketches, notes, notebooks, memoranda, reports, records, proposals, business plans, or copies of them, other
documents or materials, tools, equipment, or other property belonging to the Company or its customers which the Consultant or its personnel may then possess or have under its control. The Consultant further agrees that upon termination of its
engagement neither it nor its personnel shall take with them any documents or data in any form or of any description containing or pertaining to Confidential Information or any Inventions. 

 14. Miscellaneous. 

(a) Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties with
respect to the subject matter hereof and supersede all other prior agreements and understandings, both written and oral, between the parties with respect to such subject matter. 

(b) Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. This Agreement is not intended to confer upon any person other than the parties hereto any rights or remedies hereunder, except as otherwise expressly provided herein and shall not be assignable by operation of law
or otherwise without the non-assigning party’s prior written consent. Notwithstanding the foregoing, the Company may assign this Agreement in connection with a merger, stock purchase or the sale of all or
substantially all of the assets to which this Agreement relates. 
 (c) Amendments and Supplements. This Agreement may not be
altered, changed or amended, except by an instrument in writing signed by the parties hereto. 
 (d) No Waiver. The terms and
conditions of this Agreement may be waived only by a written instrument signed by the party waiving compliance. The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a
waiver of any such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of such party thereafter to enforce each and every such provision. No waiver of any breach of or
non-compliance with this Agreement shall be held to be a waiver of any other or subsequent breach or non-compliance. 

(e) Governing law. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of
the State of New York, without regard to its principles of conflicts of laws. 
 (f) Notice. All notices and other
communications hereunder shall be in writing and shall be deemed given if delivered by hand, sent by facsimile transmission with confirmation of receipt, sent via a reputable overnight courier service with confirmation of receipt requested, or
mailed by registered or certified mail (postage prepaid and return receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice), and shall be deemed given on the date on
which delivered by hand or otherwise on the date of receipt as confirmed: 

 To the Company: 

Pear Therapeutics, Inc. 

745 Atlantic Avenue, Floor 9 

Boston, MA 02111 
 Attention:
President & CEO 
 [***]  

To the Consultant: 
 BeHealth
Solutions, LLC 
 [***] 

(g) Remedies. The Consultant recognizes that money damages alone would not adequately compensate the Company in the event of
breach by the Consultant of this Agreement, and the Consultant therefore agrees that, in addition to all other remedies available to the Company at law, in equity or otherwise, the Company shall be entitled to injunctive relief for the enforcement
hereof. All rights and remedies hereunder are cumulative and are in addition to and not exclusive of any other rights and remedies available at law, in equity, by agreement or otherwise. 

(h) Survival; Validity. Notwithstanding the termination of the Consultant’s relationship with the Company (whether pursuant
to Section 4 or otherwise), the Consultant’s covenants and obligations set forth in Sections 6, 7, 9, 10, 11 and 12 shall remain in effect and be fully enforceable in accordance with
the provisions thereof. In the event that any provision of this Agreement shall be determined to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities,
it shall be interpreted to extend only over the maximum period of time, geographic area or range of activities as to which it may be enforceable. If, after application of the preceding sentence, any provision of this Agreement shall be determined to
be invalid, illegal or otherwise unenforceable by a court of competent jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this
Section 13(h), any invalid, illegal or unenforceable provision of this Agreement shall be severable, and after any such severance, all other provisions hereof shall remain in full force and effect. 

(i) Construction. A reference to a Section or a Schedule shall mean a Section in or Schedule to this Agreement unless otherwise
expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which shall be considered as a whole. The words “include,”
”includes” and ”including” when used herein shall be deemed in each case to be followed by the words “without limitation.” Whenever the context may require, any pronouns used herein shall
include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 

 (j) Certain definitions. 

“Field of Interest” shall mean digital therapeutics and other software-based interventions in the fields of
cognitive-behavioral therapy or relating to sleep or depression. 
 “Person” shall mean an individual, a
corporation, an association, a partnership, an estate, a trust and any other entity or organization. 
 (k) Counterparts. This
Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same Agreement. 
 IN WITNESS
WHEREOF, the parties have caused this Consulting Agreement to be executed as an agreement under seal as of the date first written above. 
  

	
	PEAR THERAPEUTICS, INC.
	
	By: ______________________________’
	Name: ____________________________
	Title______________________________

  

	
	BeHealth Solutions, LLC
	
	By:                                     
                            
	Name:______________________________
	Title:                                     
                        

 Schedule A 

Statement of Work – Comprehensive 
 1. Description
of Consulting Services. 
 The Consultant will direct the individuals below to provide Consulting Services in the form of assistance to
the Company with: 
  

	 	•	 	 Preparation of pre-submission briefing documents for submission to FDA

  

	 	•	 	 Preparation of FDA 510(k) application or other application for regulatory clearance as appropriate

  

	 	•	 	 Obtaining clinical and research data from certain educational institutions, and 

 

	 	•	 	 Otherwise as the Company reasonably requests in connection with the operation of the Company’s business.

 The Consultant will prioritize making Dr. Frances Thorndike available to provide such Consulting Services as
reasonably requested by the Company in comparison with Dr. Thorndike’s other services for Consultant and/or the University of Virginia, it being understood that to the extent Dr. Thorndike has binding commitments to the University of
Virginia, and those binding commitments shall take priority. 
 In addition, the Consultant will direct the following named personnel (the
“Key Personnel”) to provide Consulting Services: 
  

					
	 Name
	  	 Monthly Billing Rate

	1.	  	 Frances Thorndike
	  	[***]
	2.	  	 Gail Billingsley (Support Manager)
	  	[***]
	3.	  	 Carolyn Caruso (Research Support)
	  	[***]
	4.	  	 Samantha Edington (Research Assistant)
	  	[***]
	5.	  	 Alan Lattimore (Senior Software Engineer)
	  	[***]

 Without limiting the generality of the foregoing, the services requested of the Key Personnel include the
following: 
  

	 	•	 	 Assistance with technical and clinical development and commercialization efforts with respect to SHUTi

  

	 	•	 	 Facilitation of technology transfer from Consultant to the Company in connection with that certain Main
Agreement, dated as of even date herewith. 

  

	 	•	 	 Assistance with support of ongoing third party research studies that have licensed SHUTi and the Expanded Access
Program 

  

	 	•	 	 Assistance with maintenance of the platform & user support of ongoing third party research studies that
have licensed SHUTi and the Expanded Access Program 

  

	 	•	 	 Assistance with the preparation of the pre-submission briefing documents
to be submitted to the FDA. 

 2. Compensation. 

For Consulting Services during the Term, the Consultant shall be compensated [***] per month, paid monthly. The foregoing amount shall be a
flat rate paid each month. Consultant will send an invoice on a monthly basis, which lists dates and half-day segments that Consulting services were performed and a description of those services. Invoices can
be submitted to accounts@peatherapeutics.com. 
 The Company will pay the Consultant by the [***]. 

In the event that any individual providing services on behalf of Consultant works less than the minimum hours requirement of an average of 35 hours per week
for each month of the Term, or ceases to provide services via BeHealth, compensation will be adjusted on a pro-rated basis, based on the monthly compensation described for the individual in the table above.
The foregoing hours requirement includes work performed for Pear as well as a reasonable amount of time spent performing internal general administrative tasks and supporting SHUTi research customers as permitted under Section 5.2(ii) of the
Main Agreement. 

 EXHIBIT D 

Warrant Agreement 
 THIS
WARRANT NOR ANY SECURITIES THAT MAY BE ISSUED UPON EXERCISE HEREOF HAVE BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE FOREIGN OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE,
SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (i) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE ACT OR (ii) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT
AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE CORPORATION REQUESTS, AN OPINION REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL TO THE HOLDER. 

WARRANT TO PURCHASE COMMON STOCK1 

[DATE] 
 No. CSW-[#] 
 Pear Therapeutics, Inc., a Delaware corporation (the “Corporation”),
hereby certifies that, subject to the terms and conditions set forth in this Warrant to Purchase Common Stock (this “Warrant”), BeHealth Solutions, LLC, a Virginia limited liability company, its successors and assigns (the
“Holder”), is entitled to purchase up to [INSERT NUMBER OF SHARES]2 shares of Warrant Stock (as defined below) from the Corporation at any time or from time to time before the
Expiration Time (as defined below), at a purchase price per share equal to the Exercise Price (as defined below), subject to adjustment as set forth in Section 5.  

 

	1	 The terms and provisions of this form Warrant are subject to any revisions, modifications or additions
(a) as may be necessary to correct any manifest or typographical errors or inconsistencies or to comply with any applicable law, or (b) as are mutually agreed to by the Corporation and the Holder. 

	2	 The number of shares shall equal the lesser of: (A) the applicable Milestone payment amount (calculated in
accordance with Section 9.2 of that certain Assignment, License and Services Agreement between the Corporation and BeHealth Solutions, LLC, as amended from time to time (the “Core Agreement”)) divided by either
(i) prior to an IPO, the price per share at which the Corporation most recently sold capital stock of the Corporation primarily for capital raising purposes or (ii) following an IPO, the average of the closing sales prices of the Common
Stock over the 20 day period ending on the last trading day immediately preceding the issue date of the Warrant, in each case rounded down to the nearest whole share and (B) 600,000 (subject to adjustment in the event of any Warrant Stock Adjustment
Event (as defined below)) minus the number of shares of Common Stock underlying all warrants previously issued pursuant to the Core Agreement and, provided, that if the share number limit in this clause (B) applies, the warrant shall be issued
only in lieu of that portion of the Milestone payment which is equal to the total value of the warrant shares (based upon the applicable price per share of average sale price described in clause (A)), and the remaining Milestone payment shall
continue to be payable in cash pursuant to the Core Agreement. 

  

 1. Warrant Stock, Warrant Share Number and Exercise Price.  

(a) Warrant Stock. The term “Warrant Stock” shall mean the Corporation’s common stock, par value $0.0001 per
share (the “Common Stock”), or any other securities for which this Warrant becomes exercisable pursuant to the terms hereof. 

(b) Exercise Price. The exercise price per share of Warrant Stock (the “Exercise Price”) shall be $0.01, subject to
adjustment in accordance with the terms of this Warrant. 
 2. Exercise of Warrant.  

(a) Mechanics of Exercise. This Warrant may be exercised by the Holder in whole or in part by surrender to the Corporation of this
Warrant (or an affidavit and indemnity as described in Section 9(c)), with the attached subscription form duly executed by the Holder, accompanied by payment equal to the aggregate purchase price for the securities for
which this Warrant is then being exercised according to Section 3 hereof (unless this Warrant is being exercised by means of a net exercise pursuant to Section 4 hereof). If an exercise of this
Warrant pursuant to this Section 2 or Section 4 hereof is made after the Holder receives the Corporation’s written notice of any Sale of the Corporation, liquidation, dissolution or winding up
of the Corporation or an IPO, such exercise may at the election of the Holder indicated on the subscription form or in a written notice to the Corporation be conditioned upon the consummation of any such transaction, in which case such exercise
shall not be deemed to be effective until immediately prior to the consummation of such transaction. 
 (b) Warrant Agent. In the
event that a bank or trust company is appointed as trustee for the holder of this Warrant pursuant to Section 8 hereof, such bank or trust company will have all the powers and duties of a warrant agent appointed pursuant to
Section 8 hereof and will accept, in its own name for the account of the Corporation or such successor entity as may be entitled thereto, all amounts otherwise payable to the Corporation or such successor, as the case may
be, upon exercise of this Warrant. 
 (c) Expiration. This Warrant and the Holder’s rights hereunder will expire at the earliest
to occur (such time, the “Expiration Time”) of the following: (i) 5:00 p.m. (Eastern Time) on the fifth (5th) anniversary of the issuance date; (ii) upon the closing of a
Sale of the Corporation (as defined below); and (iii) the consummation of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation (provided, that the Corporation shall have provided the written notice specified in
the sentence immediately following). The Corporation shall provide at least twenty (20) days’ prior written notice to the Holder of any event set forth in clauses (ii) and (iii) of this Section 2(c) and an
IPO. Notwithstanding the foregoing, this Warrant shall, to the extent not previously exercised, automatically be deemed to have been exercised by means of a net exercise pursuant to Section 4 hereof as of immediately before
the Expiration Time or any expiration, termination or cancellation of this Warrant unless the Holder provides prior written notice to the Corporation to the contrary prior to such automatic exercise. 

  
 - 2 - 

 The term “Sale of the Corporation” shall mean (i) a sale, lease,
exclusive license or other disposition of all or substantially all of the assets of the Corporation; or (ii) a consolidation or merger of the Corporation with or into any other corporation or other entity or person, or any other corporate
reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the Corporation immediately prior to such consolidation, merger or reorganization, continue to hold at least a majority of the voting power of
the surviving entity in substantially the same proportions (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (iii) a transfer by the stockholders of the
Corporation, in a single transaction or series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Corporation’s securities), of the Corporation’s securities if, after such transfer, the
stockholders of the Corporation as of immediately prior to such transaction or series of related transactions would hold less than 50% of the outstanding voting power of the Corporation (or the surviving or acquiring entity) as of immediately
following such transaction or series of related transactions; provided, however, that neither a merger effected exclusively for the purpose of changing the domicile of the Corporation nor a sale of capital stock by the Corporation primarily
for capital raising purposes shall be deemed to be a Sale of the Corporation. 
 (d) Delivery of Certificates. As soon as is
practicable after any exercise of this Warrant, the Corporation, at its own expense, will deliver to the Holder one or more certificates for shares of Warrant Stock to which the Holder is entitled in respect of such exercise, together, in the case
of any partial exercise, with a new Warrant representing the unexercised portion hereof. Any certificate evidencing shares of Warrant Stock issued upon exercise of this Warrant shall bear a legend substantially in the following form until no longer
required by Section 9:  
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE FOREIGN OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (i) A REGISTRATION STATEMENT COVERING SUCH SECURITIES
IS EFFECTIVE UNDER THE ACT OR (ii) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE CORPORATION REQUESTS, AN
OPINION REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL TO THE HOLDER. 
 (e) Fractional
Shares. In the event that any exercise of this Warrant would, but for the provisions of this Section 2(e), result in the issuance of any fractional share of Warrant Stock, then in lieu of such fractional share the
Holder will be entitled to cash equal to the fair market value of such fractional share, as determined in good faith by the Corporation’s Board of Directors (the “Board”). 

  
 - 3 - 

 (f) Stockholder Agreements. Notwithstanding any other provision of this Warrant, it
shall be a condition precedent to the Corporation’s obligation to issue any shares of Warrant Stock upon exercise hereof that the Holder shall, to the extent requested by the Corporation, have become a party to any agreement to which the
Corporation and some or all of the holders of shares of Warrant Stock are parties (collectively, the “Stockholder Agreements”), including without limitation the Amended and Restated Voting Agreement dated December 28, 2017 by
and among the Corporation and the Stockholders parties thereto, as amended or amended and restated from time to time, and the Amended and Restated Right of First Refusal and Co-Sale Agreement dated
December 28, 2017 by and among the Corporation, the Investors parties thereto and the Key Holders parties thereto, as amended or amended and restated from time to time, in such manner as the Corporation shall request in order for the
Corporation to be able to comply with its obligations under such agreements. 
 (g) Lock-Up
Agreement. The Holder hereby agrees that it will not, without the prior written consent of the Corporation or the managing underwriter(s), during the period commencing on the date of the final prospectus relating to the registration by the
Corporation of shares of its Common Stock or any other equity securities under the Securities Act of 1933, as amended (the “Act”), on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Corporation and the managing underwriter(s) (such period not to exceed one hundred eighty (180) days in the case of the Corporation’s initial public offering
(the “IPO”) or ninety (90) days in the case of any registration other than the IPO) (the “Lock-up Period”), (i) lend; offer; pledge; sell; contract to sell; sell any
option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock (including shares of Warrant Stock) or
any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock
(including shares of Warrant Stock) or other securities, in cash, or otherwise. The foregoing provisions of this Section 2(g) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting
agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein,
and provided further that any such transfer shall not involve a disposition for value, and shall only be applicable if all officers, directors and holders of more than one percent (1%) of the outstanding capital stock of the Corporation enter into
similar agreements or are bound by similar provisions and restrictions. The underwriters in connection with such registration are intended third party beneficiaries of this Section 2(g) and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. The Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
Section 2(g) or that are necessary to give further effect thereto. The Holder further acknowledges and agrees that, to enforce the restrictions set forth in this Section 2(g), the Corporation may
impose stop-transfer instructions with respect to any shares of Warrant Stock (or other securities) subject to the restrictions in this Section 2(g) during the Lock-up Period. 

3. Payment of Exercise Price. Unless the Holder is exercising this Warrant by means of the net exercise provisions of
Section 4, the Exercise Price shall be paid by the Holder to the Corporation by wire transfer of immediately available funds pursuant to written instructions provided by the Corporation or by certified or official bank
check payable to the order of the Corporation. 

  
 - 4 - 

 4. Net Exercise. In lieu of cash exercising this Warrant, the Holder may elect to exercise this
Warrant on a “Net Exercise” basis by surrender of this Warrant to the Corporation, together with notice of such election, in which event the Corporation shall issue to the Holder a number of shares of Warrant Stock computed using the
following formula: 
  

			
		  	Y(A-B)
	X =	  	     A

 Where 
  

	 	X	 The number of shares of Warrant Stock to be issued to the Holder. 

 

	 	Y	 The number of shares of Warrant Stock with respect to which this Warrant is being exercised (inclusive of the
shares of Warrant Stock surrendered to the Corporation in payment of the aggregate Exercise Price). 

  

	 	A	 The fair market value of one share of Warrant Stock, as determined in good faith by the Board as of a date
which is within 15 days of the date of exercise; provided, however, that if the cashless exercise of this Warrant is made or deemed made in connection with a Sale of the Company or an IPO, then such fair market value shall be determined based upon
the cash and fair market value of any securities and other consideration paid in respect of each issued and outstanding share of Common Stock of the Company in connection with such Sale of the Company or the “price to public” per share of
the Common Stock specified in the final prospectus relating the IPO, whichever applies; and provided, further, however, that if this Warrant is exercised pursuant to this Section 4 following the IPO, the fair market value
shall be the closing price of a share of Common Stock on the last trading day immediately preceding the date of exercise. 

  

	 	B	 The Exercise Price (as adjusted to the date of such calculations). 

5. Adjustment for Reorganizations, Etc.  

(a) Certain Adjustments.  

(i) In case at any time or from time to time prior to the exercise of this Warrant, the Corporation effects a “Warrant Stock Adjustment
Event” (as defined below), then in each such case, (A) the number of shares of Warrant Stock purchasable hereunder shall be adjusted to the number obtained by multiplying the number of shares of Warrant Stock purchasable hereunder
immediately before such Warrant Stock Adjustment Event by a fraction, the numerator of which shall be the number of shares of Warrant Stock outstanding (excluding treasury stock) immediately after such Warrant Stock Adjustment Event and the
denominator of which shall be the number of shares of Warrant Stock outstanding (excluding treasury stock) immediately before such Warrant Stock Adjustment Event, and (B) the Exercise Price shall be adjusted to the number obtained by
multiplying the Exercise Price in effect immediately before such Warrant Stock Adjustment Event by a fraction, the numerator of which shall be the number of shares of Warrant Stock outstanding (excluding treasury stock) immediately before such
Warrant Stock Adjustment Event and the denominator of which shall be the number of shares of 

  
 - 5 - 

 Warrant Stock outstanding (excluding treasury stock) immediately after such Warrant Stock Adjustment Event,
in each case subject to further adjustment thereafter as provided herein; provided that the Exercise Price per Warrant Share shall never be less than the par value of a Warrant Share. The term “Warrant Stock Adjustment Event” shall
mean (x) the issuance of additional shares of Warrant Stock as a dividend or other distribution on the outstanding Warrant Stock, (y) the subdivision of outstanding shares of Warrant Stock into a greater number of shares of Warrant Stock,
or (z) the combination of outstanding shares of Warrant Stock into a smaller number of shares of Warrant Stock. 
 (ii) In case at any
time or from time to time prior to the exercise of this Warrant, the Corporation (A) effects a capital reorganization, exchange, conversion, substitution, reclassification, recapitalization or other change in the outstanding capital stock of
the Corporation (other than as a result of a subdivision, stock dividend or combination provided for in Section 5(a)(i) above), or any automatic or mandatory conversion of all of the outstanding shares of Warrant Stock, or
(B) consolidates with, converts into or merges with or into any other person or entity in circumstances that do not cause this Warrant to expire, then, in each such case, this Warrant shall, at any time after or simultaneously with the
consummation of such reorganization, exchange, conversion, substitution, reclassification, recapitalization, other change, consolidation or merger, as the case may be, be exercisable for, in lieu of the Warrant Stock in effect as of immediately
prior to such consummation, the cash, securities and/or other property to which such Holder would have been entitled upon such consummation if such Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment
thereafter as provided herein. In any such case, appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other
securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price payable hereunder, provided the aggregate Exercise Price shall remain the same. 

(iii) Upon each adjustment under this Section 5(a), the Corporation, at the Corporation’s expense, shall
notify the Holder in writing within a reasonable time setting forth such adjustment and the facts upon which such adjustment is based. The Corporation shall, upon written request from the Holder, furnish the Holder with a certificate of its Chief
Financial Officer, including computations of such adjustment and the Exercise Price, the securities into which this Warrant may be exercised and the number of shares of Warrant Stock for which this Warrant is exercisable in effect upon the date of
such adjustment. 
 (b) Appointment of Trustee for Warrant Holder Upon Dissolution. In the event of any dissolution of the
Corporation, the Corporation, prior to such dissolution, will, at its expense, deliver or cause to be delivered the cash, securities and/or other property receivable by the Holder after the effective date of such dissolution pursuant to this
Section 5 to a bank or trust company, as trustee for the Holder. 
 6. Representations and Warranties of the Corporation.
The Corporation hereby represents and warrants to the Holder as follows: 

  
 - 6 - 

 (a) Organization; Authority; Due Execution. The Corporation is a corporation duly
organized, validly existing, and in good standing in the State of Delaware and has the requisite corporate power and authority to own and operate its properties and to carry on its business as now conducted and as presently proposed to be conducted.
The execution and delivery of this Warrant by the Corporation and the issuance of the shares of Warrant Stock issuable upon exercise of this Warrant have been duly authorized by all requisite corporate action on the part of the Corporation. This
Warrant has been duly executed and delivered by the Corporation and constitutes the valid and binding obligation of the Corporation, enforceable against the Corporation in accordance with its terms, except to the extent that such enforcement may be
subject to applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general application relating to or affecting enforcement of creditors’ rights and laws concerning equitable remedies. The Warrant Shares, when issued
upon due exercise of this Warrant, shall be duly and validly issued, fully paid and non-assessable. 

(b) No Conflicts; Consents. The execution, delivery and performance of this Warrant, including the issuance of the shares of Warrant
Stock issuable upon exercise of this Warrant, will not result in any violation of or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any provisions of its certificate of
incorporation or bylaws or of any instrument, mortgage, indenture, judgment, order, writ, decree or contract to which it is a party or by which it is bound or, to its knowledge, of any provision of federal or state statute, law, rule or regulation
applicable to the Corporation or result in the creation of any lien, charge or encumbrance upon any assets of the Corporation or the suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or
approval applicable to the Corporation, its business or operations, or any of its assets or properties. No consents or approvals of any federal, state or local governmental authority on the part of the Corporation are required in connection with the
execution, delivery and performance or this Warrant, other than any qualifications or filings under applicable securities laws. 
 (c)
Reservation of Securities Issuable on Exercise of Warrant. The Corporation will reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, the quantity of Warrant Stock from time to time issuable upon exercise
of this Warrant. If at any time the Corporation does not have a sufficient number of authorized shares of Warrant Stock to comply with the foregoing sentence, the Corporation promptly will seek to take all steps (including, without limitation,
seeking to amend its certificate of incorporation) necessary to provide the quantity of Warrant Stock sufficient to effect the exercise in full of this Warrant. 

7. Representations and Warranties of the Holder. The Holder hereby represents and warrants to the Corporation as follows: 

(a) Entirely for Own Account. This Warrant and the shares of Warrant Stock issuable upon exercise of this Warrant (collectively,
the “Securities”) are being acquired for investment for the Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof. The Holder has no present intention of selling,
granting any participation rights in, or otherwise distributing the Securities. The Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation rights in the Securities
to such person or to any third person. The Holder has not been formed for the specific purpose of acquiring the Securities. 

  
 - 7 - 

 (b) No Public Market; Restricted Securities. The Holder understands that no public
market now exists for the Securities and that the Corporation has made no assurances that a public market will ever exist for them. The Holder understands the Securities have not been registered under the Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that the Securities must be held indefinitely unless subsequently registered under the
Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. The Holder is aware of the provisions of Rule 144 promulgated under the Act. 

(c) Experience; Etc. The Holder represents that he, she or it: (a) has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of a prospective investment in the Securities; (b) believes that he, she or it has received all the information requested from the Corporation that might be necessary or appropriate
for deciding whether to obtain the Securities; (c) has had the opportunity to discuss the Corporation’s business, management, and financial affairs with the Corporation’s management; (d) has the ability to bear the economic risks
of this investment; and (e) is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss on this investment. 

(d) Accredited Investor. The Holder hereby represents that he, she or it qualifies as an “accredited investor,” as such term
is defined in the Act. 
 8. Warrant Agent. The Corporation may, by written notice to the Holder, appoint an agent for the purpose of issuing Warrant
Stock upon exercise of this Warrant, exchanging or replacing this Warrant, or any of the foregoing, and thereafter any such issuance, exchange, or replacement as the case may be, will be made at such office by such agent. 

9. Transfer, Exchange and Replacement of Warrant.  

(a) Transfer. This Warrant may not be transferred, assigned or otherwise disposed of without the prior written consent of the
Corporation. The shares of Warrant Stock issuable upon exercise of this Warrant may not be transferred or otherwise disposed of unless (i) they have been registered or qualified pursuant to the Act and applicable foreign or state securities
laws and such disposition is made in accordance with such registration statement and any applicable requirements of state securities laws, or (ii) such disposition is made pursuant to Rule 144 or pursuant to any other exemption under the Act.
The Holder shall provide the Corporation with customary representations and other documentation reasonably acceptable to the Corporation in connection therewith, and if reasonably requested by the Corporation, the Holder shall furnish the
Corporation with a written opinion of counsel, reasonably satisfactory to the Corporation, that such disposition does not require registration of any securities under the Act; provided, however, that the Corporation will not require opinions of
counsel for transactions made pursuant to Rule 144 so long as the Corporation is provided on a timely basis with all certificates and other information the Corporation may reasonably request to permit the Corporation to determine that the subject
disposition is, in fact, exempt from the registration requirements of the Act pursuant to Rule 144. As conditions precedent to any permitted transfer of this Warrant or the Warrant Stock issuable upon exercise of this Warrant, (x) the
Corporation must be given prior written notice of such transfer stating the name and address of the transferee, (y) the applicable transferee must have agreed to be bound by all Stockholder Agreements to which the transferor, immediately prior
to such transfer, is a party and to which transferee is not already a party, and (z) with respect to transfers of this Warrant, this Warrant must be surrendered to the 

  
 - 8 - 

 Corporation, and with respect to transfers of the Warrant Stock issuable upon exercise of this Warrant, the
certificate or certificates representing such Warrant Stock must be surrendered to the Corporation or its transfer agent, in each case for cancellation. The Corporation shall deliver certificates evidencing Warrant Stock free of restrictive legends
within ten (10) days of satisfaction of the terms of this Section 9(a). Notwithstanding Section 2(d) or anything to the contrary in this Warrant, certificates evidencing the Warrant Stock
shall not be required to contain a restrictive legend if the shares of Warrant Stock are eligible for sale under Rule 144 without the requirement for the Corporation to be in compliance with the current public information required under Rule 144 as
to such securities and without volume or manner-of-sale restrictions, or if the Holder provides the Corporation with a legal opinion (and the documents upon which the
legal opinion is based) reasonably acceptable to the Corporation to the effect that the legend is not required under applicable requirements of the Act (including controlling judicial interpretations and pronouncements issued by the Staff of the
SEC). [In order to enable the Holder to sell shares of Warrant Stock under Rule 144, the Corporation covenants, at any time after it has become subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, (the
“Exchange Act”), to use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Exchange Act during the period
ending on the earlier of the Expiration Time or such time as the Warrant is exercised in full.] 
 (b) Exchange. Upon surrender of
this Warrant in connection with a transfer or exchange, in either case, otherwise permitted hereby, a new Warrant or new Warrants of the same tenor and exercisable for the same aggregate number of shares of Warrant Stock as the Warrant so
surrendered will be issued to, and registered in the name of, the transferee or transferees. The Corporation may treat the person in whose name this Warrant is registered as the Holder for all purposes. 

(c) Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Corporation of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Corporation or, in the case of mutilation, on surrender of this Warrant to
the Corporation for cancellation, the Corporation shall, within a reasonable time, execute and deliver to the Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

10. No Rights as a Stockholder. Prior to the exercise of this Warrant, the Holder shall have no rights as a stockholder of the Corporation, including,
without limitation, voting rights. 
 11. No Waiver. No failure or other delay by the Holder exercising any right, power, or privilege hereunder will
be or operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power, or privilege. 

12. No Impairment. The Corporation shall not by any action, including, without limitation, through amendment of its certificate of incorporation or any
Stockholders Agreement or any reorganization, transfer of assets, consolidation, merger, dissolution, or any other similar action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times carry
out of all such terms and take all such actions as may be necessary or appropriate to protect the rights of the Holder against impairment. 

  
 - 9 - 

 13. Notice. All notices and other communications required or permitted hereunder shall be in writing
and shall be mailed by first-class, registered or certified mail, postage prepaid, or delivered either by hand or by messenger, or sent via telecopier or e-mail, to the principal office of the Corporation and
to the attention of the Chief Executive Officer, with respect to the Corporation and to the address set forth on the signature page hereto, with respect to the Holder, or at such other address as each party shall have furnished to the other in
writing. Any notice or other communications so provided shall be deemed to be given when actually received by the addressees. 
 14. Amendments;
Waivers. This Warrant may be amended, and compliance with the provisions of this Warrant may be omitted or waived, only with the written consent of the Corporation and the Holder. 

15. Governing Law. This Warrant and all actions arising out of or in connection with this Warrant shall be governed by and construed in accordance with
the laws of the State of Delaware, without regard to principles of conflicts of law. 
 *        
*         * 

  
 - 10 - 

 Executed and delivered under seal on and as of the date first above written. 

 

			
	PEAR THERAPEUTICS, INC.
		
	By:	 	
                     
    

	Name:	 	  

	Title:	 	  

  

			
	Acknowledged and Agreed:
	
	BEHEALTH SOLUTIONS, LLC
		
	By:	 	
                     
    

	Name:	 	  

	Title:	 	  

	
	Address:

 Signature Page to Pear Therapeutics Warrant to Purchase Common Stock 

 SUBSCRIPTION FORM 

The undersigned, the Holder of the within Warrant to Purchase Common Stock, hereby elects to purchase shares of Warrant Stock (as defined in the Warrant), and
tenders the aggregate Exercise Price for such shares as follows: 
 [ ] The undersigned elects to exercise the attached Warrant by means of
a cash payment, and herewith makes payment of $             therefor. 

[ ] The undersigned elects to exercise the attached Warrant by means of the net exercise provisions of Section 4 of
the Warrant. 
 The undersigned further requests that the certificates representing such shares be issued in the name of and delivered
to                                     and if such shares
shall not include all of the shares issuable under this Warrant, that a new Warrant of like tenor and date be delivered to the undersigned for the shares not issued. 

By its execution below and for the benefit of the Corporation, the Holder hereby restates each of the representations and warranties in
Section 7 of the Warrant to Purchase Common Stock as of the date hereof. 
  

			
		 	  
 Name of Holder

		
	Dated:                                 	 	
		
		 	  
 Signature

		
		 	  
 Name of Signatory

		
		 	  
 Title of Signatory

 EXHIBIT E 

Registered IP 
 Copyright Registration No.
TXu001814325 
  

  
 31 

 EXHIBIT F 

FORM OF 
 BEHEALTH
SOLUTIONS, LLC/UNIVERSITY OF VIRGINIA PATENT FOUNDATION LICENSE AGREEMENT OF MONTH DAY, YEAR 
 This Amended and Restated Exclusive
License Agreement (“Agreement”) is entered into and made effective as of MONTH DAY, YEAR (the “Amended and Restated Effective Date”) by and between: 

University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group, a Virginia non-profit corporation, having a principal place of business at 722 Preston Avenue, Suite 107, Charlottesville, VA 22903 (“UVA LVG”); 

BeHealth Solutions, LLC (“BeHealth”), a Limited Liability Company of the Commonwealth of Virginia having a place of business
at 375 Greenbrier Dr., Suite 100, Charlottesville, VA 22901; and 
 Each a “Party” or collectively the “Parties”. 

W I T N E S E T H 
 WHEREAS, Lee
Ritterband, Frances Thorndike, and co-authors (collectively, the “Authors”) have developed certain cognitive and behavioral intervention computer-based programs as part of their employment at the
University of Virginia (“UVA” as further defined herein below); 
 WHEREAS, UVA LVG is an agent and/or assignee of the University
of Virginia; 
 WHEREAS, UVA LVG has registered copyrights to certain computer source code, documentation, and written materials which
provide and describe the function, operation and use of the computer-based intervention “Sleep Healthy Using the Internet” (hereinafter “SHUTi”, UVA LVG reference Ritterband-SHUTi), and the platform technology thereto
(hereinafter “Platform”, UVA LVG reference Ritterband-Platform) which have been developed by the Authors and which are further described in Exhibits A and B; 

WHEREAS, UVA LVG and the Université Laval (“Laval” as further defined herein below) have entered into an inter-institutional
agreement (“IIA,” attached hereto as Exhibit H) effective January 31, 2011 whereby Laval will not offer their undivided interest in and to the Licensed Copyrights (as further defined herein below) for SHUTi to any third party; 

WHEREAS, the Parties hereto have previously executed an exclusive license agreement, dated April 1, 2011 (the “Prior
Agreement”); 
 All provisions are subject to addition, elimination, or revision by either Party. All communications and discussions
are tentative until execution of a written agreement by both Parties. 

 WHEREAS, UVA LVG has been previously issued Equity in BeHealth in an amount equal to two
percent (2%) of the Equity in BeHealth that was in existence at the time of the effective date of the Prior Agreement; 
 WHEREAS, the
Parties now desire to amend and restate the Prior Agreement; 
 NOW, THEREFORE, in consideration of the premises set forth above and the
mutual covenants set forth below, the Parties hereto agree as follows: 
 Article 1 

DEFINITION OF TERMS 
 1.1 “Licensed
Content” means (i) all content in versions on or prior to October 11, 2017 (which is the most recent version release) of the intervention for insomnia entitled “SHUTi” including the names “Sleep Healthy Using The
Internet” and “SHUTi”, and (ii) all other textual material and documentation created or developed prior to October 11, 2017 (which is the most recent version release), that describes or is designed for use in conjunction
with any of the foregoing, limited to SHUTi, and as described in Exhibit A. 
 1.2 “Licensed Platform” means the RICE platform limited to Licensed
Content, in which the Licensed Software runs, and includes the research process features such as online user consent, questionnaire and module builders, automated emailing, and administrative and reporting features. 

1.3 “Licensed Software” means all binary code, source code, and logic and processes that enable the intervention to be delivered as developed as of
the Effective Date and limited to Licensed Content. Licensed Software includes algorithms, other textual material and documentation created or developed on or prior to October 11, 2017 (which is the most recent version release) that describes
or is designed for use in conjunction with any of the foregoing, limited to SHUTi, and as described in Exhibit B. 
 1.4 “Licensed Copyrights”
means the copyrights in and to the Licensed Content, Licensed Software, and/or Licensed Platform that exist under the U.S. Copyright laws and related regulations, registration for which in the U.S. Copyright Office has been applied for using the
Registration Applications attached hereto as Exhibit C. 
 1.5 “Licensed Know-How” means all the know-how embodied in and necessary to employ the Licensed Copyrights, Licensed Content, Licensed Software, and/or Licensed Platform. 

1.6 “Licensed Rights” means collectively the Licensed Content, Licensed Software, Licensed Platform, Licensed Copyrights, and Licensed Know-How. 
 1.7 “Licensed Product” means any product or service that embodies, contains, uses, or is covered by
any of the Licensed Rights, or any derivative works made by BeHealth incorporating, in whole or in material part, any of the Licensed Content, Licensed Software, Licensed Platform, Licensed Data, and/or Licensed Copyrights. 

 1.8 “Distribution” of a Licensed Product means distribution by sale or other transfer of
ownership. The terms “sale”, “sold” and “sell” as used in this Agreement include, without limitation, sales, leases, licenses, rentals, provision of services through the use of Licensed Products, and other modes of
distribution or transfer of a product or its beneficial use, including, without limitation, by internet or by internal use by BeHealth on behalf of its customers. Notwithstanding the foregoing, the “provisions of services through the use of the
Licensed Products” referenced above shall not include installation, configuration, consulting, training, support, customization, hosting, or development services. 

1.9 “First Commercial Sale” means the first Distribution to an unaffiliated third party. 

1.10 “Affiliate” means any legal entity that controls, is controlled by, or is under common control with BeHealth, and is authorized by BeHealth to
practice under the Licensed Rights. The term “control” means possession of the power to direct or cause the direction of the management and policies of another entity, whether through the ownership of at least fifty (50%) of the voting
stock or securities of the other entity, by contract, or otherwise. The term “entity” includes without limitation any individual, corporation, or other organization. 

1.11 “Sublicensee” means any non-Affiliate third party to whom BeHealth has granted a Sublicense of the
Licensed Software, Licensed Platform and/or Licensed Content. “Sublicense” means an arms-length agreement in which BeHealth: 
  

	 	(a)	 grants or otherwise transfers any of the rights granted hereunder or other rights that are relevant to the
making, using, or Distribution of Licensed Products under the non-Affiliate’s own brand, 

  

	 	(b)	 agrees not to assert the Licensed Copyrights and or agrees not to sue, prevent or seek a legal remedy for the
practice of same, 

  

	 	(c)	 assigns or otherwise transfers this Agreement other than as permitted under the Assignment article herein
below, or 

  

	 	(d)	 is under an obligation to do any of the foregoing, or to forebear from offering or doing any of the foregoing
with any other entity, including licenses, option agreements, right of first refusal agreements, standstill agreements, settlement agreements or other agreements. 

“Sublicense” does not include: (i) the grant of a license of the Licensed Software, Licensed Platform and/or Licensed Content to an end user
customer; (ii) the licensing of the rights granted hereunder or other rights that are relevant to the making, using, or Distribution of Licensed Products to a non-Affiliate under the Licensee’s
brand; (iii) the provision of the Licensed Products on a software-as-a-service (SaaS) or application service provider (ASP)
basis; or (iv) the grant of a license of any or all of the rights granted hereunder to not-for-profit and governmental institutions for their internal research and
scholarly use only. 

 1.12 “Sublicensing Revenue” means the consideration received by BeHealth from Sublicensees under a
Sublicense of the Licensed Products, including without limitation license issue fees, option fees and other licensing fees, milestone payments, minimum annual royalties, running royalties, equity or other payments of any kind whatsoever,
irrespective of whether such revenues are received in the form of cash, barter, credit, stock, warrants, release from debt, goods or services, licenses back, a premium on the sale of Equity (i.e., payments for equity that exceed the pre-Sublicense fair market value of the Equity), equity exchanges, or any other form whatsoever. 
 1.13 “Net
Sales” means the amounts received by BeHealth and its Affiliates for (i) the Distribution of Licensed Products to third parties, (ii) the reproduction and public display of Licensed Products, and (iii) the use of any of the
foregoing in BeHealth’s business, to the extent not covered hereinabove; less [***] 
 1.14 “Field” means digital therapeutic application.

 1.15 “Confidential Information” means any information exchanged between UVA LVG and BeHealth, its Affiliates and Sublicensees, (including
information disclosed by UVA on behalf of UVA LVG) either orally or in writing or other tangible medium other than that which 
  

	 	(a)	 is or becomes known to the public without fault of the Party receiving the information; 

 

	 	(b)	 the receiving Party can establish from documentary evidence that it knew prior to the receipt of the same from
the disclosing Party; or 

  

	 	(c)	 is obtained from a third party having the right to disclose same without breach of any obligation of
confidentiality to the disclosing Party. 

 1.16 “UVA” means Commonwealth of Virginia and the Rector and Visitors of the
University of Virginia, its governors, trustees, officers, agents, employees, officials, faculty, staff, and students. 
 1.17 “Laval” means the
Université Laval, its governors, trustees, officers, agents, employees, faculty, staff and students. 
 1.18 “Equity” means stock,
membership interests, partnership interests, options, warrants, other forms of convertible securities, and other ownership interests in BeHealth or its assets, as may be in existence or issued from time to time by BeHealth and/or its successors
and/or assigns. 
 1.19 “Licensed Data” means the data described in the “Data Use Agreement” set forth in Exhibit F attached hereto.

 1.20 “Related Work” means a patentable or unpatentable invention, discovery, content, software, data, or
know-how created by at least one (1) inventor or author of the Licensed Rights that (i) is directly related to sleep or sleep-related conditions, (ii) has application within the Field,
(iii) is the product of UVA research, (iv) is disclosed to UVA LVG within two (2) years of the Amended and Restated Effective Date and prior to any Change of Control, and (iv) is not otherwise obligated to any third party. 

 1.21 “Change of Control” means an acquisition of at least fifty percent (50%) of the outstanding
shares of Licensee (on a fully diluted basis) by a third-party; a merger or consolidation of Licensee with another entity; or the sale or disposition by the Licensee of substantially all of its intellectual property assets. 

Article 2 
 GRANT 

2.1 Grant to Licensee 
 In consideration
of BeHealth’s satisfaction of its obligations hereunder, UVA LVG hereby grants to BeHealth: 
  

	 	(a)	 an exclusive, worldwide right in the Field to use the Licensed Content; 

 

	 	(b)	 an exclusive, worldwide right in the Field to use the Licensed Copyrights as they relate to Licensed Content
and Licensed Software; 

  

	 	(c)	 a nonexclusive, worldwide right in the Field to use the Licensed Copyrights, but only as necessary to practice
the Licensed Content and Licensed Software; 

  

	 	(d)	 an exclusive, worldwide right in the Field to use the Licensed Software; 

 

	 	(e)	 a nonexclusive, worldwide right in the Field to use the Licensed Platform, but only as necessary to practice
the Licensed Content and Licensed Software; 

  

	 	(f)	 a nonexclusive, worldwide right in the Field to use Licensed Know-How;
and 

  

	 	(g)	 (g) subject to the Data Use Agreement by and between UVA and UVA LVG, a nonexclusive, worldwide right in the
Field to use the Licensed Data; 

 to reproduce and publicly display Licensed Products, to prepare derivative works from the Licensed
Content, Licensed Software, Licensed Platform (but only as necessary to practice the Licensed Content and Licensed Software), and/or Licensed Copyrights, and to engage in the Distribution of Licensed Products to customers throughout the term hereof.
Licensee agrees that it will comply with all of the obligations set forth in the Data Use Agreement as if Licensee was specifically identified as the Data Recipient therein. 

2.2 Affiliate Rights  
 The rights licensed to BeHealth
hereunder shall be extended to Affiliates designated in writing by BeHealth, provided that each such Affiliate first agrees in writing to be bound by the terms and conditions of this Agreement. BeHealth shall deliver to UVA LVG a copy of said
writing within thirty (30) days of its execution. BeHealth agrees to be fully responsible for the performance of such Affiliates hereunder. 
 2.3
Right to Sublicense 
 Upon achieving its First Commercial Sale of a Licensed Product, BeHealth shall have the right to sublicense any or all of the
rights licensed hereunder to non-affiliated third parties, provided that: 

	 	(a)	 each Sublicense contains the terms and conditions which are set forth in the Government Rights, and Reservation
by Licensor paragraphs, and in the Definitions, Reports and Records, Duration and Termination, Confidentiality, Representations and Warranties, Export Control, Marking and Severability articles of this Agreement, modified only to indicate that the
Sublicensee is obligated to BeHealth as BeHealth is to UVA LVG hereunder, and for the Indemnification and Insurance and Non-Use of Names articles, modified only to indicate that the Sublicensee is obligated to
UVA and UVA LVG as BeHealth is obligated to UVA and UVA LVG hereunder; 

  

	 	(b)	 BeHealth does not receive and does not agree to receive anything of value other than cash in consideration for
a Sublicense, unless expressly agreed in writing by UVA LVG after review of the proposed transaction as a whole, and in which case such value will be subject to the Sublicensing Payments provisions set forth below; 

 

	 	(c)	 each Sublicense is otherwise consistent with the terms and conditions of this Agreement; 

 

	 	(d)	 a copy of each Sublicense is provided to UVA LVG promptly following its execution, together with a written
statement disclosing any and all prior, contemporaneous, planned and proposed contractual relationships between BeHealth and the Sublicensee; and 

  

	 	(e)	 BeHealth represents and warrants that no such other contractual relationships contain consideration to BeHealth
reasonably attributable to the sublicensed rights. BeHealth agrees to be fully responsible for the performance of its Sublicensees hereunder. 

2.4 Government Rights  
 Notwithstanding
anything herein to the contrary, and without any investigation having been made, any and all licenses and other rights granted hereunder are limited by and subject to the rights and requirements of the United States Government which may attach as a
result of Government sponsorship of research at UVA or Laval in which one or more authored work covered by the Licensed Rights was created, as set forth in the relevant Government research contracts with UVA and in the applicable U.S. statutes, and
as such rights and requirements may be amended or modified by law. 
 2.5 Reservation by Licensor 

Notwithstanding anything herein to the contrary, the above grant is subject to a reservation of rights by UVA LVG for itself, UVA and Laval to
practice under the Licensed Rights for educational, research and other internal purposes. UVA LVG further excludes from the license granted herein the right to bring an infringement action against, seek monetary damages from, or seek an injunction
against, any Author or their present or future not-for-profit employers even after such employment has ended, for infringement of the portion of the Licensed Rights of
which they are the Author in carrying out not-for-profit research. Nothing herein shall be construed to require UVA LVG to bring any such action against any such party.
Each Author shall have the right to bring the most current version of any Licensed Content, Licensed Software, and/or Licensed Platform of which he/she is an author at the time of their departure from UVA or Laval to their future not for profit
employers to use for not-for-profit research only. A list of Authors associated with the Licensed Software, Licensed Platform, and Licensed Content is attached hereto as
Exhibit D. 

 2.6. Licenses Back 

BeHealth hereby provides UVA LVG (with respect to the portion of the Licensed Rights of which they are or were a UVA Author, as set forth in
Exhibit D) a non-transferable, revocable, limited license to derivative works created by BeHealth during the term of this Agreement that incorporate the Licensed Content, Licensed Software, and/or Licensed Platform, subject to UVA LVG so licensed
entering into a Non-Disclosure Agreement with BeHealth with terms sufficient to protect the commercial viability of BeHealth and/or Licensed Products. Such license shall be a limited license for internal
research use only. However, BeHealth shall not be required to provide maintenance and support services or hosting services to UVA or Laval, and any such services shall be subject to a separate agreement. The Parties acknowledge and agree that
BeHealth is not obligated to provide any services with respect to the License Back, including, without limitation, configuration, installation, customization, hosting, maintenance and support, such services to be provided only pursuant to a separate
agreement. 
 2.7 UVA Derivative Works  

Nothing herein shall be construed to require UVA, Laval or UVA LVG to maintain the Licensed Software and/or Licensed Platform or to make any
derivative works therefrom. 
 2.8 Related Work 

UVA LVG will attempt to identify and disclose each Related Work, if any, to BeHealth. Upon disclosure of a Related Work by UVA LVG to
BeHealth, BeHealth shall have a [one hundred twenty (120)] day exclusive option to negotiate terms of a license or amendment to this Agreement to include the Related Work for commercial purposes in the Field (“Related Works License”); and
in connection with the foregoing, UVA LVG agrees to negotiate in good faith towards executing such Related Works License. Each Related Works License shall, if appropriate, (i) provide UVA LVG with commercially reasonable financial
consideration, (ii) obligate BeHealth to use commercially reasonable efforts to commercialize the subject Related Work in accordance with mutually agreed diligence milestones, and (iii) incorporate or include all other terms of this
Agreement. 
 Article 3 

FINANCIAL CONSIDERATION 
 In
consideration of the rights, privileges, and licenses granted hereunder, BeHealth shall pay royalties to UVA LVG in the manner hereafter provided: 
 3.1
Initial Equity Transfer  
 (Intentionally Left Blank) 

3.2 Running Royalties  
 Throughout the
term of this Agreement, BeHealth shall pay quarterly to UVA LVG a running royalty of [***] of Net Sales of Licensed Products containing at least a material portion of the Licensed Content, and [***] of Net Sales of all other Licensed Products. 

 The above royalty shall apply to all Licensed Products distributed during the term of this Agreement. No
multiple running royalties shall be payable because the Licensed Product, or the manufacture or use thereof, are or shall be covered by more than one Licensed Right. 

3.3 Minimum Annual Royalties  
 BeHealth
shall pay to UVA LVG a Minimum Annual Royalty payment in the amount of [***] annually. BeHealth shall make such payment to UVA LVG within thirty (30) days of the end of the calendar year in which it is due. For each calendar year, that
year’s Minimum Annual Royalty payment shall be fully creditable against running royalties paid to UVA LVG under the Running Royalties section for such calendar year, but shall not be creditable against any other payment due under this
Agreement, including past or future running royalties that may be or may become due. 
 3.4 Sublicensing Payments 

BeHealth shall pay to UVA LVG an amount equal to [***] of Sublicensing Revenues. BeHealth shall not pay a running royalty on Net Sales of
Licensed Products by its Sublicensees. 
 3.5 Buyout Payment 

At any point in time after the Effective Date, BeHealth shall be entitled to make a one-time lump sum
payment to UVA LVG of one million dollars (U.S. $1,000,000) in exchange for a perpetual royalty free license in the Field to all Licensed Rights covered by this Agreement at the time of payment. If BeHealth makes this payment, then no sublicensing
fees based on Sublicensing Revenue shall be owed under this Agreement. 
 Article 4 

DILIGENCE 
 4.1 Commercialization Program 

 BeHealth shall use its commercially reasonable efforts to bring the Licensed Products to market through a thorough, vigorous, and
diligent commercialization program, which program shall include but not be limited to the development, marketing, promotion, distribution and sale of Licensed Products. A report of BeHealth’s efforts, and progress made, in bringing Licensed
Products to market shall be provided to Foundation in accordance with the Diligence Reporting paragraph below. 
 4.2 Diligence Milestones  

(Intentionally Left Blank) 
 4.3
Diligence Reporting 
 Throughout the course of commercial development of Licensed Products by BeHealth and its Affiliates, BeHealth
shall provide UVA LVG with reasonably detailed confidential periodic summary reports evidencing its efforts in, progress made, and future plans for, its development of Licensed Products and bringing same to market (such reports to be provided no
less frequently than twice per year, the first report to be due within 12 months after the Effective Date). 

 Article 5 

REPORTS AND RECORDS 
 5.1 Record Accounting

 BeHealth shall keep complete and accurate books of account containing all particulars that may be necessary for the purpose of showing
the amounts payable to UVA LVG by BeHealth hereunder, and for otherwise verifying BeHealth’s performance hereunder. Such books of account shall be kept at BeHealth’s principal place of business, and shall be maintained for at least five
(5) years following the end of the reporting period to which they pertain. Such books and the supporting data shall be open at all reasonable times to the inspection by UVA LVG’s internal auditing personnel, and/or an independent certified
public accountant retained by UVA LVG and/or employed by UVA LVG, for the purpose of verifying BeHealth’s royalty statement or compliance in other respects with this Agreement. Such examinations shall be made during reasonable business hours,
and not more than once during each calendar year. BeHealth shall also provide UVA LVG with a comparable right of audit of each Affiliate and Sublicensee. Should any of the foregoing examinations reveal an underpayment, BeHealth shall immediately pay
to UVA LVG the underpaid amount and interest due thereon (as provided for herein). Should the underpayment be more than five percent (5%), then BeHealth shall also bear the cost of such examination, including accountant’s fees and expenses, and
BeHealth shall immediately reimburse UVA LVG for all such audit costs. 
 5.2 Product Reports  

Within thirty (30) days of the end of each fiscal quarter, BeHealth shall deliver to UVA LVG complete and accurate reports, giving such
particulars of the business conducted by BeHealth and its Affiliates during the preceding three-month period under this Agreement as shall be pertinent to a royalty accounting hereunder. These reports shall include at least the following: 

 

	 	(a)	 The numbers of each Licensed Product distributed by BeHealth and each Affiliate and Sublicensee;

  

	 	(b)	 Total receipts for Licensed Products distributed by BeHealth and each Affiliate and Sublicensee;

  

	 	(c)	 Deductions applicable as provided in the definition of Net Sales; 

 

	 	(d)	 Total royalties due to UVA LVG; 

 

	 	(e)	 Names and addresses of all Sublicensees of BeHealth; 

 

	 	(f)	 Payments and other consideration received from each Sublicensee, as further described in the definition of
Sublicensing Revenues; and 

  

	 	(g)	 Payments due to UVA LVG under the Sublicensing Payments paragraph hereinabove. 

 In addition to the foregoing reports, BeHealth shall deliver annually a report containing
BeHealth’s financial statements for the preceding twelve (12) months including, at a minimum, a balance sheet and an operating statement. Such reports shall be considered Confidential Information, and shall be subject to the
confidentiality provisions contained herein. 
 5.3 Payments  

With each quarterly report submitted, BeHealth shall pay to UVA LVG the royalties and other payments due and payable under this Agreement. If
no royalties shall be due, BeHealth shall so report. Payments shall be paid in United States Dollars in Charlottesville, Virginia, or at such other place as UVA LVG may reasonably designate consistent with the laws and regulations controlling in any
foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate stated in the Wall Street Journal on the last business day of the calendar
quarterly reporting period to which such royalty payments relate. Unless otherwise specified hereunder, all payments shall be made within forty-five (45) days after the end of the calendar quarter in which they became due and payable to UVA
LVG. Any amounts due hereunder which are unpaid thirty (30) days after the end of the calendar quarter shall bear simple interest accrued at the annual rate of twelve percent (12%). Any taxes required to be withheld by BeHealth from payments
otherwise due hereunder in order to comply with the tax laws of the United States or any other country shall be promptly paid by BeHealth to the appropriate tax authorities, and BeHealth shall furnish UVA LVG with true copies of official tax
receipts or other appropriate evidence issued by the appropriate tax authorities sufficient to enable UVA LVG to support a claim for income tax credit or refund in respect of any sum so withheld. 

Article 6 
 COPYRIGHT PROTECTION

 6.1 Intellectual Property Ownership 

All Licensed Rights shall at all times be owned by UVA LVG, except for the SHUTi Licensed Content which shall at all times be owned jointly by
UVA LVG and Laval. UVA LVG will conduct an initial assessment of the copyrights which may be required to protect the Licensed Software and/or Licensed Content, including an estimate of the necessary costs of filing and attorney fees. BeHealth shall
cover the costs of filing fees and attorney’s fees associated with the filing, prosecution and issuance of copyright registrations covering the Licensed Software and/or Licensed Content. If BeHealth does not agree to pay such costs and UVA LVG
proceeds to incur those costs at its own expense, the rights at issue will thereafter be excluded from the rights granted thereunder, and UVA LVG shall be free to license such rights to third parties, without any further obligation to BeHealth.
BeHealth shall own all BeHealth-made derivative works of the Licensed Content, Licensed Software, and/or Licensed Platform. However, BeHealth’s rights in and to the same shall be subject to UVA LVG’s, and if applicable, Laval’s
dominant rights in and to the Licensed Content, Licensed Software, and/or Licensed Platform. 

 6.2 Infringement of Licensed Copyrights  

If either Party believes that any of the Licensed Copyrights are being infringed by a third party, such Party shall notify the other, and as
part of such notice shall provide copies of all documentary evidence of such infringement. BeHealth will have the right but not the obligation to bring an infringement action against the alleged infringer, at BeHealth’s sole expense. UVA LVG
will cooperate as requested by BeHealth, and will be compensated by BeHealth for its reasonable out-of-pocket expenses, which UVA LVG will only be required to expend if
BeHealth has approved same for reimbursement. No settlement, consent judgment, or other voluntary final disposition of such suits may be entered into without the consent of UVA LVG, which consent shall not be unreasonably withheld. Any damages paid
(including without limitation statutory damages, lost profits damages, compensatory damages, exemplary damages, increased damages, and awards of costs and attorney’s fees) shall first be proportionately applied to the reimbursement of
BeHealth’s reasonable costs, expenses and legal fees, including amounts BeHealth has reimbursed to UVA LVG. The remaining balance of such damages shall be divided as follows: (i) for that remaining portion, if any, which was awarded on the
basis of lost profits, UVA LVG shall recover the royalty UVA LVG would have received under this Agreement if the infringing distributions or reproductions had been made by BeHealth, multiplied by the proportion of any increase relative to the actual
damages awarded due to willfulness, and BeHealth shall retain the remainder; and (ii) for any other remaining recovery, equally between BeHealth and UVA LVG. In the event that BeHealth elects not to bring or pursue an infringement action
against an alleged infringer, UVA LVG, and if applicable, Laval shall have the right, but not the obligation, to do so at its sole expense, and to retain all recovered damages. In such instances BeHealth will cooperate as requested by UVA LVG, and
will be compensated by UVA LVG for its reasonable out-of-pocket expenses, which BeHealth will only be required to expend if UVA LVG has approved same for reimbursement.

 Article 7 
 DURATION AND
TERMINATION 
 7.1 Contract Term  
 The
term of this Agreement shall commence on the Effective Date and shall otherwise continue unless terminated in accordance with the provisions herein below. 

7.2 Bankruptcy 
 BeHealth will promptly
inform UVA LVG of its intention to file a voluntary petition in bankruptcy or of another’s communicated intention to file an involuntary petition in bankruptcy. Subject always to BeHealth not being in material breach of the Agreement, all
rights and licenses granted under or pursuant to any section of this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, 11 U.S.C. § 101 et seq., licenses of rights to “intellectual
property” as defined under Section 101(35A) of the Bankruptcy Code; and Software and Platform are, and shall be deemed to be, “embodiment[s]” of “intellectual property” for purposes of same. BeHealth shall retain and
may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any other jurisdiction. Without limiting the generality of the foregoing, UVA LVG acknowledges that the rights and license granted to BeHealth
pursuant to this Agreement shall not be affected by UVA LVG’s rejection of this Agreement in bankruptcy, and shall continue subject to the terms and conditions of this Agreement. 

 7.3 Licensor Termination  

If BeHealth fails to make an undisputed payment to UVA LVG of running royalties or any other payment in accordance with the terms of this Agreement, or upon
BeHealth’s other material breach or default of any material term of this Agreement (except for termination due to any breach of provision of the Indemnification and Insurance article herein below), UVA LVG shall have the right to serve notice
upon BeHealth of UVA LVG’s intention to terminate the entirety of the rights, privileges and licenses granted hereunder within sixty (60) days from the mailing of such notice. If BeHealth does not timely pay all such overdue amounts to UVA
LVG, or, as applicable, if BeHealth fails to reasonably cure such material breach or default and to timely provide UVA LVG with reasonably acceptable written evidence of such cure, then the rights, privileges, and licenses granted hereunder may be
immediately terminated by UVA LVG at any time after said sixty (60) day period by written notice to BeHealth. Such termination shall be effective as of the date of mailing of said termination notice. 

7.4 Termination by BeHealth  
 BeHealth
shall have the right to terminate this Agreement, in whole or with respect to any Licensed Rights, at any time by providing UVA LVG with thirty (30) days advance notice by certified mail, provided BeHealth has not committed a material and
uncured breach of this Agreement. Upon such termination, UVA LVG shall be free to license such rights to third parties, without any further obligation to BeHealth whatsoever. All licenses granted to customers in accordance with the terms of this
Agreement shall survive termination of this Agreement. 
 7.5 Continued Obligations  

Upon termination of this Agreement in whole or in part for any reason, nothing herein shall be construed to release either Party from any
obligation that matured prior to the effective date of such termination. Except as set forth in the Lapse of Coverage paragraph herein below, after the effective date of such termination, BeHealth and its Affiliates and Sublicensees may, for a
period of one (1) year, distribute and publicly display all Licensed Products, and complete Licensed Products in the process of reproduction at the time of such termination and distribute and publicly display the same, provided that
(i) BeHealth shall pay to UVA LVG the running royalties and other payments as required hereinabove, (ii) insurance required hereunder shall be in effect, and (iii) BeHealth shall submit the reports required by the Product Reports
paragraph hereof. 
 7.6 Effect on Sublicenses  
 Upon
termination of this Agreement in whole or in part, for any reason, BeHealth shall promptly notify its Sublicensees of such termination. Subsequent to termination, BeHealth shall no longer have the authority to grant any sublicenses hereunder. Any
rights previously granted by BeHealth under any sublicense hereunder will be automatically revoked ninety (90) days following the effective date of termination of this Agreement. However, Sublicensees shall have the right to enter into a
written license agreement with UVA LVG before their sublicense is revoked, through which such Sublicensee shall become bound to UVA LVG on substantially the same terms and conditions as it was bound to BeHealth under the sublicense. If any
Sublicensee desires to enter into such a license agreement, it shall 

 
be wholly the responsibility of that Sublicensee to notify UVA LVG of such desire within thirty (30) days after the effective date of termination of this Agreement. UVA LVG hereby agrees to
offer such terms and enter into such written license agreement with modifications as is reasonably necessary to accommodate the functional and structural differences between BeHealth and UVA LVG. Failure of a Sublicensee to timely enter into such a
license shall automatically result in the termination of the sublicense and all rights granted thereunder. 
 7.7 Survivability 

The provisions of the Financial Considerations, Confidentiality, Indemnification and Insurance, Representations and Warranties, Export Control
and Non-Use of Names articles of this Agreement shall survive termination of this Agreement. Nothing herein shall be construed to release either Party from any obligations that matured prior to the effective
date of such termination. 
 Article 8 

CONFIDENTIALITY 
 8.1 Confidential Information
 
 During the term of this Agreement and for a period of five (5) years thereafter, the Parties agree that all Confidential
Information shall be maintained in confidence by the receiving Party and shall not be disclosed by the receiving Party to any third parties unless agreed to in writing by the Party providing the information; nor shall any such Confidential
Information be used by the receiving Party for any purpose other than those contemplated by this Agreement; except, however, the Parties agree that nothing herein will be construed to prevent (i) the Parties from providing about this Agreement
and amounts paid as part of other routinely prepared summary documents, and (ii) UVA LVG from reporting consideration received hereunder to UVA ,the Authors and, if applicable, Laval. 

8.2 Security 
 BeHealth and UVA LVG agree
that the confidentiality obligations hereunder shall require that each Party use those security and confidentiality procedures and practices as each would use for its own confidential records. BeHealth acknowledges that UVA and UVA LVG are separate
entities, that these confidentiality provisions do not bind UVA, and that the protection of BeHealth’s confidential information may require BeHealth to enter into a separate confidentiality agreement with UVA. 

8.3 Publication  
 In recognition of the
academic mission of UVA, BeHealth agrees that nothing herein shall prevent UVA or UVA LVG from disclosing or publishing UVA or UVA LVG information, or create any legal liability for doing so, irrespective of whether such information comprises UVA or
UVA LVG Confidential Information. Notwithstanding the foregoing, the UVA LVG shall not publish the source code of the Licensed Software or Licensed Platform or a material part of the Licensed Content. 

 Article 9 

ARBITRATION AND GOVERNING LAW 
 9.1 Law to
Govern 
 This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Virginia, without regard
to its or any other jurisdiction’s conflicts of laws provisions. 
 9.2 Arbitration Proceedings  

Claims, disputes, or controversies concerning the validity or scope of any of the Licensed Copyrights shall be resolved in the Federal
District Court seated in Charlottesville, Virginia. All other claims, disputes or controversies arising under, out of, or in connection with this Agreement, which have not been resolved by good faith negotiations between the Parties, shall be
resolved by final and binding arbitration in Charlottesville, Virginia, under the rules of the American Arbitration Association. The arbitrators shall have no power to add to, subtract from, or modify any of the terms or conditions of this
Agreement. Any award rendered in such arbitration may be enforced by either Party in the courts of the Commonwealth of Virginia seated in Charlottesville. The Parties hereby irrevocably consent and submit to the exclusive jurisdiction and venue of
each court and arbitration site cited above for the purposes each is mentioned. UVA LVG agrees not to terminate any portion of this Agreement during any arbitration proceedings under this section. 

9.3 Arbitration Delays  
 The arbitrators
shall not delay the arbitration proceeding for the purpose of obtaining, or permitting either Party to obtain, judicial resolution of such issue, unless a court of competent jurisdiction enters an order staying such arbitration proceeding. Neither
Party shall raise any issue concerning the validity or scope of any copyright or trademark licensed hereunder in any proceeding held to enforce any arbitration award hereunder or in any proceeding otherwise arising out of any such arbitration award.

 Article 10 
 INDEMNIFICATION
AND INSURANCE 
 10.1 Licensee Indemnification  

BeHealth agrees to indemnify, hold harmless and defend UVA and UVA LVG, and their respective trustees, officers, employees, attorneys and
agents from all claims or demands made against them (and any related losses, expenses or attorney’s fees) arising out of or relating to BeHealth’s or Affiliate’s conduct or possession, use, Distribution, or other disposition of the
Licensed Products, the Licensed Rights, or Confidential Information, including but not limited to, any claims of product liability, personal injury, death, damage to property or violation of any law or regulation. This obligation shall survive
termination of this Agreement. “BeHealth” includes any and all of its parents, assigns, successors, officers, trustees, personnel, agents, and employees. 

10.2 Extent of Insurance 
 BeHealth shall
obtain and maintain liability insurance that shall have total liability limits of not less [***] for claims by third parties seeking damages as a result of death, injury to person or damage to property. BeHealth shall require each of its authorized
Affiliates and Sublicensees to have such insurance or its equivalent. Evidence of the existence and sufficiency of such insurance shall be provided to UVA LVG upon request. 

 Neither BeHealth nor any Affiliate shall Distribute or publicly display any Licensed
Product, Licensed Software, or Licensed Platform, unless BeHealth (and BeHealth’s permitted assignee) shall have first provided UVA LVG with a certificate of insurance proving that BeHealth has in force, during the term of this Agreement, the
liability insurance described in the immediately preceding paragraph. Upon the request of UVA LVG, Licensee shall provide UVA LVG with a copy of the policy, status of claims and claims history respecting any of the insurance required to be
maintained by Licensee hereunder. 
 Such policy or policies provided by BeHealth shall name UVA LVG and UVA as additional insured parties,
and such policy or policies shall be primary to any other insurance available to the UVA LVG or UVA, and contain a provision that the required coverage will not be reduced, materially altered, or canceled by BeHealth without the prior written
approval of the Executive Director of UVA LVG. Any reduction or material alteration of such coverage without written approval, or any other violation of the provisions of this paragraph, shall be deemed a material breach of this Agreement. 

The professional liability coverage and commercial general liability coverage required by this Paragraph shall be in substantially similar to
the form attached to this Agreement as Exhibit E, or for BeHealth’s permitted assignee, similar to the requirements attached to this Agreement as Exhibit I. Provided BeHealth obtains and maintains liability coverage substantially similar to the
form attached to this Agreement it shall for all purposes be deemed to have satisfied the requirements of this Article 10.2. 
 10.3 Term of
Insurance 
 Unless expressly waived in writing by UVA LVG, BeHealth agrees that the liability insurance described in Article 10.2 shall
be continuously maintained in force for so long as this Agreement remains in effect and for a period of up to five (5) years after termination of this Agreement. 

10.4 Lapse of Coverage 
 This Agreement and the licenses
granted herein to BeHealth shall immediately and automatically terminate without notice in the event BeHealth, or its Affiliates, Sublicensees or other party acting under authority of BeHealth, fails to obtain the insurance required in Article 10.2,
or if the insurance lapses or is cancelled. A termination occurring under this paragraph shall occur and become effective at the time such insurance coverage ends or becomes required and is not obtained. Nothing herein shall be construed to release
either Party from any obligation that matured prior to the effective date of such termination. Notwithstanding the foregoing, to the extent that automatic termination resulted from a lapse of the above-required insurance, and to the extent that such
rights are still available for licensing, BeHealth shall have the right to reinstate the effectiveness of this Agreement by obtaining the required insurance within sixty (60) days from the lapse, whereupon this Agreement shall automatically
become effective as of the date of reinstatement of said insurance (occurring within sixty (60) day period from the lapse) and shall remain in full force and effect without any further action of the Parties. 

 10.5 Sublicensee Insurance  

BeHealth shall insert this Indemnification and Insurance article in any sublicense in which BeHealth grants to a third party the right to
reproduce, distribute or display any Licensed Product or to prepare derivative works based on any Licensed Content, Licensed Software, Licensed Platform, and/or Licensed Copyrights, with the name of such Sublicensee substituted for the name of
BeHealth therein, and to name UVA and UVA LVG as insured Parties with respect to the Distribution of use of Licensed Products. 
 Article 11

 REPRESENTATIONS AND WARRANTIES 
 11.1 No
Encumbrances  
 Each Party hereto acknowledges and agrees that no representation or promise not expressly contained in this Agreement
has been made by the other Party hereto or by any of its agents, employees, representatives or attorneys concerning the subject matter of this Agreement. Each Party further warrants and represents that, to the best of its knowledge, it has the full
right and power to make the promises and grant the licenses set forth in this Agreement and that there are no outstanding agreements, assignments or encumbrances in existence which are inconsistent with the provisions of this Agreement. 

11.2 Licensee Warranty 
 BeHealth
warrants and represents that it shall use its best efforts to diligently pursue the development, manufacture, and Distribution of Licensed Products throughout the term of this Agreement. 

11.3 Licensor Warranty 
 UVA LVG hereby
represents and warrants to BeHealth that it is, to the best of UVA LVG’s knowledge, the owner of all Licensed Rights, except as indicated in the Intellectual Property Ownership paragraphs hereinabove, free and clear of any claims or
encumbrances, except as indicated in the Government Rights and the Reservation by Licensor paragraphs hereinabove, and has the exclusive right to grant the licenses provided herein. 

11.4 Infringement Actions by 3rd Parties  

BeHealth acknowledges and agrees that, except as warranted above, all rights licensed by UVA LVG hereunder are licensed “as is” and without any
representation, indemnification or warranty with respect to possible infringement of third party rights. In the event of a third party infringement action against either Party with respect to any Licensed Product, BeHealth will indemnify the UVA LVG
against such action and shall without limitation pay any damages resulting from any judgment against UVA LVG. BeHealth’s indemnification shall be limited to the amount of BeHealth’s Net Sales from the Licensed Product resulting in such
claim unless BeHealth knowingly violated the third party’s intellectual property rights in which case BeHealth’s indemnification obligation shall not be so limited. In any event, UVA LVG will cooperate as requested by BeHealth, and will be
compensated by BeHealth for its reasonable out-of-pocket expenses incurred in such cooperation, which UVA LVG will only be required to expend if BeHealth has approved
same for reimbursement. No settlement, consent judgment, or other voluntary final disposition of any suit that would affect the validity, scope or enforceability of the Licensed Copyrights, by estoppel, admission or otherwise, or UVA LVG’s
rights in or to same, may be entered into without the consent of UVA LVG. 

 11.5 Disclaimers  

Except as warranted above, nothing in this Agreement shall be construed as (i) a warranty or representation by UVA LVG or Laval as to the
validity or scope of any Licensed Rights, (ii) a warranty or representation that anything distributed, developed, used or promoted under any license granted in this Agreement does not or will not infringe patents, copyrights, trademarks, trade
secrets or other proprietary rights of third parties; (iii) an obligation to bring or prosecute actions or suits against third parties for infringement; (iv) conferring the right to use in advertising, publicity or otherwise any trademark,
trade name, or names, or any contraction, abbreviation, simulation or adaptation thereof of BeHealth, UVA, UVA LVG, or Laval; (v) conferring by implication, estoppel or otherwise any license or rights under any rights of UVA LVG or Laval other
than the Licensed Rights; (vi) any other representations or warranties, either express or implied, unless specified in this Agreement; (vii) directly or indirectly operating or applying as a waiver of sovereign immunity by the Commonwealth
of Virginia; or (viii) imposing any obligation or any liability on any Party contrary to the laws of the Commonwealth of Virginia. UVA LVG DISCLAIMS AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE WITH RESPECT TO THE LICENSED RIGHTS OR ANY LICENSED PRODUCTS. 
 Article 12 

PAYMENTS AND NOTICES 
 Any
payment, notice, or other communication given under this Agreement shall be in writing and shall be deemed delivered when sent by certified first class mail, overnight courier, or by facsimile, provided that a copy of such facsimile is promptly sent
by certified first class mail or overnight courier, addressed to the Parties as follows (or at such other addresses as the Parties may notify each other in writing): 
  

			
	Licensee:	  	UVA LVG:
	BeHealth Solutions, LLC	  	UVA LVG
	[***]	  	[***]

 Article 13 

NO ASSIGNMENT 
 BeHealth shall
neither assign nor transfer this Agreement or any interest herein without the prior written consent of UVA LVG. BeHealth shall give UVA LVG written notice of BeHealth’s intent to so transfer this Agreement thirty (30) days prior to
completion of such transfer, along with a copy of such transfer agreement, pursuant to which such transferee shall have agreed in writing to be bound by the terms and conditions of this Agreement. Upon the first transfer and assignment of this
Agreement by BeHealth in accordance with this Article 13, BeHealth (and not the transferee) shall pay to UVA LVG an assignment fee of fair consideration to be mutually agreed upon by 

 
the Parties; provided, however, that no assignment fee shall be due in connection with any subsequent transfer and assignment of this Agreement to a third party. Upon completion of the first such
transfer, the term “BeHealth” as used herein shall be deemed to be such transferee. If such transferee shall not have agreed in writing to be bound by the terms and conditions of this Agreement, then UVA LVG shall have the right to
terminate this Agreement. 
 Article 14 

NON-USE OF NAMES 

Neither Party shall use the names of the other, of Laval or any adaptation thereof, or of their employees, officers, or agents, or any
adaptation thereof, in any advertisement, promotional or sales literature without prior written consent obtained from such Party in each case. However, BeHealth may state that it licensed from UVA LVG the Licensed Rights, and UVA LVG may state that
it licensed to BeHealth the Licensed Rights. Either Party may further include (i) Authors’ names, (ii) software titles and summaries, (iii) technology field of use, (iv) results of research studies related to the Licensed
Rights, (v) information about the publication of articles about the Licensed Rights in scientific and non-scientific publications (subject to the intellectual property rights of the owners of those
publications), (vi) that the Licensed Content, Licensed Software, and Licensed Platform were developed at UVA and, if applicable, Laval with funding from the National Institute of Health (NIH), and (vii) the type and extent of the license, but
may not include terms and conditions of this Agreement, or other Confidential Information, unless such disclosure is required by law, rule or regulation. The Parties agree to take all reasonable precautions to prevent any such public information
regarding the Licensed Rights or this Agreement from containing inaccuracies or from otherwise being misconstrued or misleading, and such information shall clearly indicate the Party responsible for the conception of the Licensed Rights, and the
ongoing research and development efforts at BeHealth, UVA and, if applicable, Laval. 
 Article 15 

EXPORT CONTROLS 
 It is understood that UVA LVG
and BeHealth are subject to United States laws and regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979) controlling the export of technical data, computer software, laboratory prototypes, and
other commodities, and that such obligations hereunder are contingent on compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of
the United States Government and/or written assurances by BeHealth that BeHealth shall not export data or commodities to certain foreign countries without prior approval of such agency. UVA LVG does not represent that a license is not required, or
that, if required, such a license shall be issued. 

 Article 16 

MARKING 
 BeHealth shall mark with
copyright notices all Licensed Products made or distributed in the United States in accordance with 17 U.S.C. §401, and will mark all Licensed Products made or distributed in other countries in accordance with the laws and regulations then
applicable in each such country. 
 Article 17 

FORCE MAJEURE 
 No Party shall be
liable for any failure to perform as required by this Agreement, to the extent such failure to perform is caused by acts of God or natural disaster, interference by civil or military authorities,
non-administrative government actions, and war or terrorism. 
 Article 18 

SEVERABILITY 
 Should any
provision of this Agreement be determined to be unenforceable or otherwise unlawful, then such provision shall be without effect, and the remaining terms of this Agreement shall survive, as if such provision had not been included herein; and the
Parties shall promptly meet to agree upon further terms which shall, within the confines of the law, most substantially satisfy the intention of the Parties as reflected by the ineffective provision. If such agreement between the Parties is not
reached within thirty (30) days of the date such provision is determined to be unenforceable or otherwise unlawful, the Parties agree to submit such matter to binding arbitration in accordance with the arbitration provisions hereinabove. 

Article 19 
 HEADERS 

The article and paragraph headings contained in this Agreement are for reference purposes only, and shall not in any way affect the meaning or
interpretation of this Agreement. 
 Article 20 

BENEFIT AND WAIVER 
 This
Agreement is binding upon and shall inure to the benefit of the Parties hereto, their representatives, successors and permitted assigns. No failure or successive failures on the part of the Parties, to enforce any provisions of this Agreement, and
no waiver or successive waivers on either Party’s part of any condition of this Agreement, shall operate as a discharge of such provision or condition, or render the same invalid, or impair the right of such Party to enforce same in the event
of any subsequent breach or breaches by the other Party. 

 Article 21 

ENTIRE AGREEMENT 
 The Parties
hereto acknowledge that this Agreement sets forth the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and supersedes any and all prior written and oral agreements, understandings, promises or offers,
including without limitation any term sheet which preceded its drafting, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the Parties hereto and explicitly referencing this
Agreement and specifying that it is the Parties’ intent to modify the terms and/or conditions set forth herein. The Parties acknowledge that invoices, purchase orders or other mechanisms for administering any payment or other obligation set
forth herein shall not contain terms and conditions separate from, in addition to, and/or in conflict with this Agreement, and that any such terms, if present, shall be void and without effect, and shall not be enforceable by any Party hereto. The
initial drafting of this Agreement by UVA LVG was for the convenience of both Parties, and both Parties agree that such fact shall not result in any of the above clauses being construed against UVA LVG should such clauses become in dispute. 

 BEHEALTH SOLUTIONS, LLC/UNIVERSITY OF VIRGINIA PATENT FOUNDATION 

LICENSE AGREEMENT OF MONTH DAY, YEAR 

IN WITNESS WHEREOF, the Parties hereto have agreed and accepted the terms and conditions of, and have duly executed this Agreement to be made
effective as of the Effective Date. 
  

			
	University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group	  	BeHealth Solutions, LLC
		
	By:
                                         
       	  	By:
                                         
       
	Name: [***]________________	  	Name:
                                         
       
	Title: Executive Director______	  	Title:
                                         
       
		
	Date:__________________________	  	Date:__________________________
		
	By:
                                         
       	  	Address for Notices:
		  	[***]
	Name:
                                         
       	  	
	Title:
                                         
       	  	
		
	Date:__________________________	  	
		
	Address for Notices:	  	
		
	UVA LVG	  	
	[***]	  	
		
	Attention: Executive Director	  	
	[***]	  	

 Exhibit A 

Description of Licensed Content 
 SHUTi
Description:  
 [***] 

 Exhibit B 

Description of Licensed Platform 
 THE PLATORM:

 Research Infrastructure Containing E-Interventions (RICE) 

Prepared By: [***] 
 Revised and Updated By: [***] 

What is RICE? 
 RICE is a collection of tools and
services. The tools are presented to create a truly reusable framework for Internet based interventions. This document gives a high level description of the following components of RICE: 

[***] 

 Exhibit C 

Copyright Registration Applications 

[***] 

 All provisions are subject to addition, elimination, or revision by either Party. All
communications and discussions are tentative until execution of a written agreement by both Parties. 
 Exhibit D 

Authors of Licensed Content, Licensed Software, Licensed Platform 

Licensed Content: 
 SHUTi: [***] 

Licensed Software: 
 [***] 

Licensed Platform: 
 [***] 

 Exhibit E 

Professional Liability Coverage 

[***] 

 Exhibit F 

AGREEMENT 
 Data Use Agreement
between UVA and UVA LVG 
 This agreement (the “Agreement”) is made and entered into as of March 22, 2018 (the “Effective Date”) by
and between The Rector and Visitors of the University of Virginia, a not-for-profit educational institution with offices at Office of Sponsored Programs, 1001 North
Emmet Street, Charlottesville, Virginia 22903 (the “University”) and the University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group, a Virginia
non-profit corporation, having a principal place of business at 722 Preston Avenue, Suite 107, Charlottesville, VA 22903 (the “Data Recipient”, and together with University, the “Parties”).

 University is a health care provider subject to the Health Insurance Portability and Accountability Act of 1996, as codified as 42 U.S.C. 1320d
(“HIPAA”) and any current and future regulations promulgated thereunder. This Agreement is designed to permit the disclosure or use of the following proprietary and confidential documents: (1) Regulatory Filings, (2) Protocols,
(3) De-Identified Data Sets (as defined by HIPAA) and (4) Summaries for the studies identified on Exhibit G, incorporated by reference, (collectively, the “Data Set”) for purposes set forth
below. All terms used but not otherwise defined in this Agreement shall have the same meaning as those terms in corresponding regulations. 
 This Agreement
sets forth the terms and conditions pursuant to which the University will disclose the Data Set to the Data Recipient. 
  

	 	1.	 The University may, but is not required to, provide Data Recipient access to the Data Set. Any transfer of the
Data Set is contingent upon and subject to approval by University’s internal reviews and approvals, as applicable. 

  

	 	2.	 Except as otherwise specified herein, the Data Recipient may make use of the Data Set only for granting a
limited, nontransferable (except as permitted under Article 13 of the Agreement), non-exclusive sub-license to BeHealth Solutions, LLC (“BeHealth”) consistent
with terms and conditions provided for herein. 

 This Agreement expressly permits BeHealth (or its permitted assignee
under Article 13 of the Agreement) to use or grant a limited, nontransferable, nonsublicensable, sub-license to all or a portion of the Data Set, for any and all commercial purposes solely for use in
connection with the commercialization of the Licensed Rights within the Field of Use, as those terms are defined in the License Agreement entered into between Data Recipient and BeHealth and all subsequent amendments, to one or more collaborators,
partners, agents or subcontractors on substantially similar terms and conditions provided for herein. This Agreement expressly prohibits any such collaborator, partner, agent or subcontractor that receives a
sub-license to all or a portion of the Data Set to grant any further rights, license or sublicense in or to the Data Set, without UVA LVG’s express, written consent (such consent not to be unreasonably
withheld). 

  
 Page 28 

 All provisions are subject to addition, elimination, or revision by either Party. All
communications and discussions are tentative until execution of a written agreement by both Parties. 
  

	 	3.	 The Parties agree that the Data Set should not include Protected Health Information (PHI) (as that term is
defined under HIPAA) and that if any PHI is inadvertently disclosed to Data Recipient, then Data Recipient will abide by all HIPAA requirements that would apply to University with respect to PHI. 

 

	 	4.	 The Data Recipient agrees to not use or disclose the Data Set other than as permitted by this Agreement or as
otherwise required by law. 

  

	 	5.	 The Data Recipient agrees to use appropriate safeguards to prevent the use or disclosure of the Data Set other
than as provided for by this Agreement. 

  

	 	6.	 The Data Recipient agrees to promptly report to the University in writing any use or disclosure of the Data Set
not provided for by this Agreement, of which it becomes aware. 

  

	 	7.	 The Data Recipient agrees to ensure that any agent or sub-licensee,
including but not limited to a subcontractor, collaborator or partner, to whom it provides information from the Data Set agrees to the same restrictions and conditions that apply through this Agreement to the Data Recipient with respect to such
information. 

  

	 	8.	 Data Recipient agrees to destroy or return all the Data Set, including copies and incorporations thereof, at
the completion of the purpose identified in Section 2 or termination of this Agreement for any reason. 

  

	 	9.	 This Agreement may be terminated by the University upon five (5) days written notice to the Data Recipient
if the Data Recipient materially breaches any provision contained in this Agreement and such breach is not cured within the five (5) day period. 

  

	 	10.	 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS NOR EXTENDS ANY
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH REGARD TO THE DATA SET OR ANALYSIS TO BE SUPPLIED HEREUNDER. THERE ARE NOT EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT USE OF ANY DATA SET OR
ANALYSIS WILL NOT INFRINGE ON ANY THIRD PARTY RIGHTS. NEITHER PARTY MAKES ANY REPRESENTATIONS AS TO THE USEFULNESS OF THE DATA OR ANALYSIS AND IF THE OTHER PARTY CHOOSES TO USE SUCH DATA OR ANALYSIS IT DOES SO AT ITS OWN RISK. 

 

	 	11.	 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR INCIDENTAL, SPECIAL, INDIRECT, LOST PROFITS, LOST
REVENUE, LOST OPPORTUNITY OR CONSEQUENTIAL LOSS, DAMAGE OR EXPENSE ARISING FROM OR IN RELATION TO THIS AGREEMENT, OR THE RESEARCH, WHETHER IN WARRANTY, CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE OR OTHERWISE. THIS LIMITATION SHALL
APPLY EVEN IF SUCH PARTY HAS BEEN ADVISED OR IS AWARE OF THE POSSIBILITY OF SUCH DAMAGES. 

  

  
 Page 29 

 All provisions are subject to addition, elimination, or revision by either Party. All
communications and discussions are tentative until execution of a written agreement by both Parties. 
  

	 	12.	 The Parties are acting as independent contractors with respect to this Agreement, and this Agreement shall not
create any agency, joint venture, or employee-employer relationship between the Parties. Except to the extent prohibited by law, Data Recipient and any sub-licensees assume all liability for damages which may
arise from their use of the Data Set. University will not be liable to the Data Recipient or any sub-licensees for any loss, claim or demand made by the Data Recipient or any sub licensees, or made against the
Data Recipient or any sub-licensees by any other Party, due to or arising from the use of the Data Set, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the
University. Nothing contained in this Agreement shall be deemed an express or implied wavier of the sovereign immunity of the University or the Commonwealth of Virginia. 

 

	 	13.	 University is and shall remain the owner of the Data Set. For the avoidance of doubt, Data Recipient’s
rights in and to the Data Set are non-exclusive. 

  

	 	14.	 Confidentiality 

  

	 	a.	 “Confidential Information” means any information relating to the Data Set and any information
disclosed to Data Recipient in connection with performance of this Agreement. 

  

	 	b.	 Confidential Information does not include information that (i) has been published or is published
hereafter, unless such publication is a breach of this Agreement; (ii) is received by Data Recipient from a third party not under an obligation of confidentiality with respect thereto; or (iii) is independently developed by Data
Recipient’s employees who did not have access to Confidential Information. 

  

	 	c.	 Data Recipient shall maintain the confidentiality of all Confidential Information and not use or exploit it for
any purpose not expressly permitted herein, until fifteen (15) years after termination of this Agreement. Data Recipient shall protect Confidential Information from disclosure and unauthorized use with the same care used to protect its most
valuable confidential information but in no event less than reasonable care. 

  

	 	d.	 Upon termination of this Agreement, Data Recipient shall return to University all originals and copies of all
materials (other than this Agreement) containing any Confidential Information. Data Recipient may, however, retain one archival copy of any such information in its legal department for purposes of legal compliance only. 

 

	 	15.	 This Agreement may not be modified, amended, or discharged, in whole or in part, except by an agreement in
writing signed by both Parties. 

  

	 	16.	 This Agreement is made under, and shall be construed in accordance with, the laws of the Commonwealth of
Virginia. Any legal action involving this Agreement will be adjudicated in the state courts of the Commonwealth of Virginia. 

  

  
 Page 30 

	 	17.	 This Agreement supersedes all prior agreements, written or oral, between the Parties relating to the subject
matter of this Agreement. 

  

	 	18.	 Each paragraph and provision of this Agreement is severable from the entire Agreement; and if any provision is
declared invalid, the remaining provisions shall nevertheless remain in effect. 

  

	 	19.	 This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all
of which together shall constitute one and the same document. This Agreement may be executed by Facsimile or electronic copies (i.e. PDF). The Parties agree that Facsimile or electronic copies of signatures have the same effect as original
signatures. 

  

	 	20.	 The term of this Agreement shall begin on the Effective Date and end twenty (20) years from the Effective
Date; provided, however, that obligations regarding confidentiality shall survive termination or expiration of this Agreement pursuant to Section 16. Additionally, any confidentiality or privacy obligations required by applicable law that apply
to the Data Set shall survive indefinitely pursuant to applicable law. 

 IN WITNESS THEREOF, the Parties hereby cause this
Agreement to be executed, effective as of the date of the last signature below. 
 University of Virginia Patent Foundation 

d/b/a University of Virginia Licensing & Ventures Group 
  

			
	By:	 	  

		 	[***]
		 	Executive Director
		
	Date:	 	  

	
	The Rector and Visitors of
	The University of Virginia
		
	By:	 	  

		 	[***]
		 	Assistant Director of Contracts
		
	Date:	 	  

 Exhibit G 
  

	1.	 R01MH086758: An Internet Intervention for Insomnia: Efficacy and Dissemination. 2010-2016. Principal
Investigator (Ritterband). National Institutes of Health / National Institute of Mental Health (Direct + Indirect = $2,885,606). IRB-HSR# 15704: An Internet Intervention for Insomnia: Efficacy and
Dissemination. 

 Exhibit H 

Inter-Institutional Agreement 

Between Laval and UVA LVG 
 [***]

 Exhibit I 

Insurance Coverages 
  

	1.	 General. Licensee shall obtain and maintain, in full force and effect and at Licensee’s sole cost
and expense one or more insurance policies providing: 

  

	 	a)	 Commercial general liability insurance (including coverage and any necessary endorsements for products
/completed operations as well as for clinical trials if any such trials are to be performed by or on behalf of Licensee) which provides, for each annual policy period, coverage of no less than the minimum limits specified below for injury, death and
property damage resulting from each occurrence during the policy period; and 

  

	 	b)	 Worker’s compensation insurance in respect of all of Licensee’s employees with limits of liability
and coverage not less than statutory limits provided by the Commonwealth of Virginia or other applicable laws and regulations; and 

  

	 	c)	 Automobile liability insurance to cover owned and non-owned
automobiles. 

  

	2.	 Policy Limits. Subject to the further provisions of this Section, the commercial general liability and
products liability coverages shall have the following minimum limits: 

  

	 	a)	 Commercial general liability: [***] each occurrence, [***] general aggregate. Licensee shall have sixty
(60) days following the Effective Date to obtain such coverage. 

  

	 	b)	 Products liability: [***] aggregate. Licensee shall have sixty (60) days following the Effective Date to
obtain two million dollars in aggregate. Licensee shall have ninety (90) days following the Effective Date to obtain the additional million dollars in aggregate. 

 

	 	c)	 Cyber Liability [***] aggregate. Licensee shall have sixty (60) days following the Effective Date to
obtain such coverage 

  

	 	d)	 UVA LVG may periodically evaluate the adequacy of the minimum coverage of insurance and coverage limits
specified in this Agreement. UVA LVG reserves the right to require Licensee to adjust the insurance coverage by modifying the types of required coverages, the limits and/or financial rating and/or the method of financial rating of Licensee’s
insurers as such changes are required of UVA LVG by its insurance carrier. UVA LVG shall provide Licensee with reasonable notice, contingent on UVA LVG receiving timely notice from its insurance carrier, of any proposed modification and, if so
requested by Licensee, discuss any proposed modifications in good faith. 

  

	3.	 Policy Specifics. Each policy of insurance required by this Agreement shall: 

 

	 	a)	 be issued by reputable and financially secure insurance carriers having at least an A-rating (A- rating or above by A.M. Best) and an A.M. Best Class Size of at least VIII, 

 

	 	b)	 list each of UVA and UVA LVG, their respective trustees, officers, employees, faculty, staff, students, agents
and their respective successors, heirs and assigns as additional insureds, 

  

	 	c)	 be endorsed to provide that the insurer waives all subrogation rights it has or may have against any additional
insured, and 

	 	d)	 be primary in respect of all additional insureds. 

 

	4.	 Evidence of Insurance. Within thirty (30) days following the Effective Date, and thereafter no
later than the day on which any such policy of insurance is renewed or replaced, Licensee shall provide UVA LVG with a Certificate of Insurance from each such insurer which evidences compliance by Licensee with its obligations hereunder. Upon the
request of UVA LVG, Licensee shall provide UVA LVG with a copy of the policy, status of claims and claims history respecting any of the insurance required to be maintained by Licensee hereunder. Further, Licensee will not cancel or fail to renew the
identified insurance without giving UVA LVG at least thirty (30) days’ prior written notice thereof. 

  

	5.	 Clarifications. For the avoidance of doubt, the minimum insurance coverage and limits set forth in this
Agreement do not constitute a limitation on Licensee’s liability or obligations to indemnify or defend UVA LVG and UVA and any other additional insured under this Agreement.Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT
(this “Agreement”), dated as of the 1st day of October, 2021, is by and between COMSovereign Holding Corp.,
a Nevada corporation (the “Company”), and Frances
M. Jandjel (the “Executive”), the Company and the Executive are sometimes referred to herein individually
as a “Party” and collectively as the “Parties.”

 

WITNESSETH

 

WHEREAS, the Company and its
subsidiaries and affiliates design, build and support infrastructures for the technology and telecommunications industries and the aerostat
and drone industry (the “Business”);

 

WHEREAS, the Company has developed
and will develop relationships with Customers, Prospective Customers, Vendors, suppliers and shippers as well as a reputation in the technology
and communications industries and the aerostat and drone industry, which are and will become of great importance and value to the Company
in connection with its Business, and the loss of or injury to the Business will result in substantial and irreparable damage to the Company;

 

WHEREAS, the Company has acquired
and/or developed certain trade secrets and Confidential Information, as more fully described below, and has expended significant time
and expense in acquiring or developing its trade secret or Confidential Information; and expends significant time and expense on an ongoing
basis in supporting its employees, including the Executive; and

 

WHEREAS, in the course of
the Executive’s employment by the Company, the Executive may receive, be taught or otherwise have access to items and information
associated with the Business such as sales, purchasing, transportation, documentation, marketing and trading techniques, information and
materials, customer and supplier lists or information, correspondence, records, financial information, pricing information, computer systems,
computer software applications, business plans and other information which is confidential and proprietary.

 

NOW, THEREFORE, in consideration
of the forgoing, the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency
of which the Parties hereby acknowledge, the Parties hereby agree as follows:

 

1. Adoption
of Recitals. The Company and Executive hereto adopt the above recitals as being true and correct.

 

2. 
Employment. The Company shall employ the Executive, and the Executive shall accept such employment with the Company, upon the terms
and conditions set forth in this Agreement for the period beginning on October 1, 2021 (the “Effective Date”) and ending
as provided in Section 6 hereof (the “Employment Period”).

 

    1

     

    

 

3. Position
and Duties.

 

(a) During
the Employment Period, the Executive shall (i) serve the Company in the capacity of Chief Financial Officer (“CFO”) and Executive
Vice President, and (ii) have such duties, responsibilities and authorities consistent with his position and as the Company’s CEO
or his or her designee may from time to time confer and direct (collectively, the “Duties”).

 

(b) The
Executive shall devote his full business time, effort and energy to the affairs of the Company and the discharge of the Duties.

 

4. Compensation.
Base Compensation. the Company shall pay the Executive an annual base salary in the amount of not less than $225,000.00, calculated
and paid in accordance with the Company’s standard practices and policies in effect from time to time. The Executive’s annual
base salary, as may be adjusted from time to time, is hereinafter referred to as the “Base Salary”.

 

5. Additional
Benefits.

 

(a) Equity
Participation.  Executive shall be eligible for such grants of awards (the “Share Awards”) under the terms of the
Company’s 2020 Long-Term Incentive Plan, or any stock option, other equity incentive plan, or any successor or replacement plan
(the “Plan”) as adopted by the Board and approved by the Company’s stockholders, and as the Compensation Committee of
the Corporation may from time to time determine. Executive shall be granted and receive Share Awards at such times and levels consistent
with Share Awards granted to other senior level executives of the Company, from time to time. Executive acknowledges that the grant of
the Option shall at all times be subject to the terms and conditions of the Plan and Option Agreement. 

 

(b) Expenses.
the Company shall reimburse the Executive for all reasonable expenses incurred by her in the course of performing the Duties, to the extent
consistent with the policies established by the Company from time to time with respect to travel and other business expenses, subject
to the Company’s requirements with respect to reporting and documentation of such expenses. The Executive’s right to reimbursement
for expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for reimbursement during
any calendar year shall not affect the expenses eligible for reimbursement in any other calendar year, (ii) reimbursement shall be made
not later than December 31 of the calendar year following the calendar year in which the expense was incurred, and (iii) the right to
reimbursement is not subject to liquidation or exchange for any other benefit.

 

(c) Benefits.
The Executive shall be entitled to participate in such benefit plans as the Company provides to its employees from time to time in accordance
with the Company policies, except to the extent that such plans are duplicative of benefits otherwise provided to the Executive under
this Agreement (e.g., a severance pay plan). Such participation will be subject to the terms and conditions of such plans, and any other
restrictions or limitations imposed by law.

 

(d) Vacation
and Other Leave.  During the Employment Period, the Executive’s annual rate of vacation accrual shall be
four (4) weeks per year, with such vacation to accrue and be subject to the Company’s vacation policies in effect from time to time,
including any policy which may limit vacation accruals and/or disallows the carryover from year to year of accrued but unused vacation
to.  The Executive shall also be entitled to all other holiday and leave pay generally available to other executives of the Company.

 

    2

     

    

 

6. Term.

 

(a) Subject
to earlier termination pursuant to this Section 6, the Employment Period shall continue from the Effective Date for an initial term of
one (1) year, and shall automatically renew annually thereafter for subsequent one (1) year terms, unless either the Company or the Executive
provides written notice of non-renewal to the other Party not later than sixty (60) days prior to the last day of the then-current term.

 

(b) Notwithstanding
the foregoing, the Employment Period shall earlier terminate under the following circumstances: (i) the Executive’s death or “Permanent
Disability” (defined as the expiration of a continuous period of 120 days during which the Executive is unable to perform all
of the Duties due to physical or mental incapacity); (ii) the Agreement is terminated for Cause (as defined below) by the Company at any
time upon notice to the Executive setting forth in reasonable detail the nature of the cause; (iii) the Agreement is terminated for Good
Reason (as defined below) by the Executive in accordance with the timing requirements specified below; (iv) the Agreement is terminated
by the Company without Cause at any time upon notice to the Executive; or (v) the Agreement is terminated by the Executive without Good
Reason upon fourteen (14) days’ prior written notice to the Company (provided that the Company may elect to waive such notice period
or any portion thereof; but in that event, the Company shall pay the Base Salary for that portion of the notice period so waived).

 

(c) For
purposes of this Agreement, “Cause” shall mean, as determined by the Company in its reasonable judgment, (i) the failure
or refusal by the Executive to perform his lawful Duties (other than any such failure resulting from the Executive’s incapacity due to
illness) which, if capable of cure, has not been cured within fifteen (15) business days after written notice of such breach delivered
to the Executive by the Company; (ii) the Executive’s material breach of this Agreement, any other agreement between her and the
Company (including without limitation the Non-Competition Agreement, as defined below) or any material policy of the Company or its affiliates
applicable to her that has been communicated to her in writing which, if capable of cure, has not been cured within fifteen (15) business
days after written notice of such breach delivered to the Executive by the Company; (iii) the Executive’s willful misconduct or
gross negligence with respect to the performance of the Duties, which, if capable of cure, has not been cured within fifteen (15) business
days following written notice of such violation delivered to the Executive by the Company; (iv) the Executive’s conviction, or plea
of guilty or nolo contendere, with respect to any felony, or any act of fraud, theft, or financial dishonesty with respect to the
Company or any of its affiliates, customers or business partners, or any other crime involving dishonesty, disloyalty or fraud; or (v)
habitual alcohol or substance abuse by the Executive.

 

(d) For
purposes of this Agreement, “Good Reason” shall exist upon (i) mutual written agreement by the Executive and the Company
that Good Reason exists, or (ii) reduction of the Executive’s annual base salary without the prior consent of the Executive; provided,
however, that in order for employment to terminate for Good Reason, (A) the Executive must provide written notice to the Company, setting
forth in reasonable detail the nature of the condition giving rise to Good Reason, within thirty (30) days of the initial existence of
such condition, (B) the condition must remain uncured for a period of thirty (30) days following such notice and (C) the Executive must
terminate his employment, if at all, not later than thirty (30) days after the expiration of such cure period.

 

(e) In
the event of any dispute regarding the existence of the Executive’s Permanent Disability hereunder, the matter will be resolved
by a physician qualified to practice medicine and has no prior knowledge of the Executive, which physician shall be selected by the Company
and be reasonably acceptable to the Executive or his representative. For this purpose, the Executive will submit to all appropriate medical
examinations and any determination by such a physician will be final and conclusive of the issue for all purposes of this Agreement.

 

    3

     

    

 

7. Matters
Related to Termination.

 

(a) Final
Compensation. In the event of termination of the Executive’s employment hereunder, howsoever occurring, the Company shall
pay to the Executive (i) the Base Salary for the final payroll period of the Executive’s employment, through the date of
termination and (ii) reimbursement for business expenses incurred by the Executive but not yet paid to the Executive as of the date
of termination, provided that the Executive submits all expenses and supporting documentation required within thirty (30) days of
the date of termination, and provided further that such expenses are reimbursable under Company policies as then in effect (all of
the foregoing, “Final Compensation”). All Final Compensation shall be paid to the Executive at the time
prescribed by law or applicable Company policies for such payment, but in no event more than sixty (60) days following the date of
termination.

 

(b) Severance. In
the event that the Executive’s employment terminates pursuant to Section 6(b)(iii) or 6(b)(iv) hereof, the Company will pay to
the Executive, in addition to Final Compensation, six (6) months of the Base Salary (the “Severance Payments”).
Notwithstanding the foregoing, any obligation of the Company to provide the Severance Payments is conditioned on the
Executive’s signing and returning to the Company a timely and effective separation agreement containing a release of all
claims against the Company and other customary terms (the “Separation Agreement”). The Separation Agreement must
become effective, if at all, by the sixtieth (60th) calendar day following the date of termination. The Severance
Payments will be in the form of salary continuation, payable in accordance with the normal payroll practices of the Company. The
first payment, which shall be retroactive to the date immediately following the date of termination, will be made on the first
regularly scheduled payroll date that follows the expiration of sixty (60) days from the date of termination.

 

(c) Benefits Termination.
Except for any right that the Executive may have under the federal law known as “COBRA” (and any applicable state or local
laws) to continued participation in the Company’s group health plans at his cost, the Executive’s participation in all employee
benefit plans shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of employment,
without regard to any continuation of base salary or other payment to the Executive following termination, and the Executive shall not
be eligible to earn vacation or other paid time off following the termination of employment.

 

8. Section
409A. Notwithstanding any other provision herein to the contrary, to the extent that any payment to be made to the Executive, whether
pursuant to this Agreement or otherwise, is determined to constitute “nonqualified deferred compensation” within the meaning
of and subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) such payment shall
not be made prior to the date that is the earlier of (i) six months and one day after the Executive’s separation from service with
the Company and affiliate or subsidiary of the Company and (ii) the Executive’s death; except to the extent of (A) payments that
do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation
by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good faith discretion);
(B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or
benefits that are not subject to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The terms of this
Section 8 shall apply only if the Executive is a “specified employee” (within the meaning of Section 409A) on the date of
such separation from service, and shall only apply to the extent the delay of such payment is necessary to prevent such payment from being
subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Each payment made under this Agreement shall be
treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a
series of separate payments. In no event shall the Company have any liability relating to the failure or alleged failure of any payment
or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.

 

    4

     

    

 

9. Ownership
of Works; Infringement Indemnity.

 

(a) Assignment
of Works. Executive agrees to promptly make full written disclosure to the Company, to hold in trust for the sole right and benefit
of the Company, and hereby assigns, transfers, grants and conveys to the Company, all of his worldwide right, title, ownership and interest
in and to any and all designs, trademarks, inventions, original works of authorship, findings, conclusions, data, discoveries, developments,
concepts, improvements, trade secrets, techniques, processes, know-how and other work product, whether or not patentable or registrable
under copyright or similar laws, which Executive may solely or jointly conceive or develop or reduce to practice, or cause to be conceived
or developed or reduced to practice, in the performance of this Agreement or which result, to any extent, from use of the Company’s
premises or property (collectively, the “Works”), including any and all intellectual property rights inherent in the
Works and appurtenant thereto including, without limitation, all patent rights, copyrights, trademarks, know-how and trade secrets (collectively,
“Intellectual Property Rights”). Executive further acknowledges and agrees that all original works of authorship which
are made by her in the performance of this Agreement and which are protectable by copyright are “works made for hire,” as
that term is defined in the United States Copyright Act and belong solely to the Company. Executive agrees that all Works developed by
Executive during the course of this Agreement, or developed in future using Works as the basis, are the sole property of the Company.
However, to the extent that any such work may not, by operation of any applicable law, be a work made for hire, Executive hereby assigns,
transfers and conveys to the Company all of his worldwide right, title and interest in and to such Work, including all Intellectual Property
Rights therein and appurtenant thereto. Executive hereby waives any and all “moral rights” that he may have in any of the
Works under the Berne Convention or any other applicable law, rule or regulation. Executive agrees that he will retain no rights in any
of the Works or any of the Intellectual Property Rights in or relating thereto. Executive agrees that the Company owns the entire right,
title, ownership and interest in and to all of the Works and all Intellectual Property Rights in or relating thereto including, without
limitation, the right to reproduce the Works, modify the Works, prepare derivative works based upon the Works or the copyright or any
other Intellectual Property Rights in or relating thereto, sell or otherwise distribute the Works. Executive warrants that all of the
Works and all Intellectual Property Rights in or related thereto are free and clear of all liens, security interests, claims and other
encumbrances of any type.

 

(b) Further
Assurances. Upon the request and at the expense of the Company, except as provided below, Executive shall execute and deliver any
and all instruments and documents and take such other acts as may be reasonably necessary to document the assignment and transfer described
in Section 9(a) above or to enable the Company to secure its rights in the Works and any Intellectual Property Rights in or relating thereto
in any and all jurisdictions, or to apply for, prosecute and enforce patents, trademark registrations, copyrights or other Intellectual
Property Rights in any and all jurisdictions with respect to any Works, or to obtain any extension, validation, re-issue, continuance
or renewal of any such Intellectual Property Right. Whether any Intellectual Property Rights in or relating to any of the Works will be
preserved, maintained, or registered in any jurisdiction shall be at the sole discretion of the Company.

 

(c) Attorney in Fact.
If the Company is unable, after reasonable effort, to secure Executive’s signature as required in Section 9(b) for any reason whatsoever,
Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his agent and attorney-in-fact,
to act for and in Executive’s behalf and stead to execute and file any such application or applications or other documents and to
do all other lawfully permitted acts to further the prosecution and issuance of a patent, copyright or trademark or any other legal protection
thereon with the same legal force and effect as if executed by Executive. 

 

    5

     

    

 

10. Covenants.

 

(a) Definitions.

 

(i) The
term the “Company” shall mean COMSoveregin Holding Corp. and its subsidiaries, affiliates and related entities. It is
understood that any subsidiaries, affiliates or related entities of the Company are intended third-party beneficiaries of the provisions
of this Agreement.

 

(ii) The
term “Confidential Information” shall include, but not be limited to: Customer lists and Prospective Customer lists;
specific information on Customers and Prospective Customers (including information on purchasing preferences, credit information, and
pricing); terms and conditions under which the Company deals with Vendors and supplier or prospective Vendors or suppliers; employee and
independent contractor lists; the Company’s sources of supply; the Company’s billing rates; pricing lists (including item
and Customer specific pricing information); names of agents; operations; contractual or personnel data; trade secrets; license agreements;
proprietary purchasing and sales methods and techniques; proprietary compositions, ideas and improvements; pricing methods and strategies;
computer programs, computer systems, computer data, system documentation, special hardware, product hardware, related software development
and computer software design and/or improvements; methods of distribution; market feasibility studies; proposed or existing marketing
techniques or plans; sales and sales volumes; purchasing, transportation, documentation, marketing and trading techniques of Customers,
potential Customers and/or Vendors; inventions (including Works and Intellectual Property Rights as defined above); future the Company
business plans; project files; design systems; information on current and potential Vendors including, but not limited to, their identity,
pricing, and purchasing information not generally known; personal information about the Company’s executives, officers and directors;
correspondence, and letters, notes, notebooks, reports, flowcharts, proposals, processes and/or any and all other confidential or proprietary
information belonging to the Company or relating to the Company’s business and/or affairs; and (ii) any information that is of value
or significance to the Company that derives independent economic value, actual or potential, from not being generally known to, and not
being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, including information
not generally known to the competitors of the Company nor intended by the Company for general dissemination. Confidential Information
shall not include any: (a) information known generally to the public (other than as a result of unauthorized disclosure by the Executive);
(b) information that became available from a third party source and such source is not bound by a confidentiality agreement; (c) any information
not otherwise considered by the Board of Directors of the Company to be Confidential Information; (d) information which is subsequently
independently conceived or developed by Executive without use or reference to Confidential Information; or (e) information which is generally
applicable business or industry know-how or acumen of Executive’s which does not embody and is not predicated upon the Confidential
Information.

 

(iii) The
term “Customer” shall mean any person or entity which has purchased goods, products or services from the Company, entered
into any contract for products or services with the Company, and/or entered into any contract for the distribution of any products or
services with the Company within the one (1) year immediately preceding the termination of the Executive’s employment with the Company
for whatever reason; provided that such goods, products or services must be substantially related to the Business.

 

(iv) The
phrase “directly or indirectly” shall include the Executive either on his/her own account, or as a partner, owner,
promoter, joint venturer, employee, agent, consultant, advisor, manager, executive, independent contractor, officer, director, stockholder,
or otherwise, of an entity.

 

    6

     

    

 

(v) The
term “Non-Compete Period” shall mean the period beginning on the date hereof and ending on the date that is twelve
(12) months immediately following the termination of the Executive’s employment with the Company for whatever reason.

 

(vi) The
term “Prospective Customer” shall mean any person or entity which has expressed material interest in purchasing goods,
products or services from the Company, expressed material interest in entering into any contract for products or services with the Company,
and/or expressed material interest in entering into any contract for the distribution of any products or services with the Company within
the one (1) year immediately preceding the termination of the Executive’s employment with the Company for whatever reason; provided
that such goods, products or services must be substantially related to the Business.

 

(vii) The
term “Restricted Area” shall include any geographical location anywhere in the world where the Executive has been assigned
to perform services on behalf of the Company during the Term and where the Company, its affiliates or subsidiaries are engaged in the
Business.

 

(viii) The
term “Restricted Business” shall mean any business that competes with the Company in the Business, as such business
now exists or as it may exist at the time of the termination of the Executive’s employment with the Company for whatever reason.

 

(ix) The
term “Vendor” shall mean any supplier, person, or entity from which the Company has purchased products or services
during the one (1) year immediately preceding the termination of the Executive’s employment with the Company for whatever reason;
provided that such products or services must be substantially related to the Business.

 

(b) Non-Competition.
During the Non-Compete Period, in the Restricted Area, the Executive shall not, directly or indirectly, engage in, promote, finance, own,
operate, develop, sell or manage or assist in or carry on in any Restricted Business, provided, however, that the Executive may at any
time own securities of any competitor corporation whose securities are publicly traded on a recognized exchange so long as the aggregate
holdings of the Executive in any one such corporation shall constitute not more than 5% of the voting stock of such corporation.

 

(c) Non-Solicitation
of Employees or Independent Contractors. During the Non-Compete Period, the Executive shall not, directly or indirectly, solicit or
attempt to induce any employee of the Company or independent contractor engaged and/or utilized by the Company in any capacity to terminate
his/her employment with, or engagement by, the Company. Likewise, during the Non-Compete Period, the Executive shall not, directly or
indirectly, hire or attempt to hire for another entity or person any employee of the Company or independent contractor engaged and/or
utilized by the Company in any capacity.

 

    7

     

    

 

(d) Non-Solicitation
of Customers, Prospective Customers, or Vendors. During the Non-Compete Period, the Executive shall not, directly or indirectly, sell,
design, build, or support network infrastructures for the technology and telecommunications industries to any Customer, Prospective Customer,
or Vendor of the Company through any entity other than the Company. The Executive acknowledges and agrees that the Company has substantial
relationships with its Customers, Vendors and Prospective Customers, which the Company expends significant time and resources in acquiring
and maintaining, and that the Company has Confidential Information pertaining to its business and its Customer, Vendors and Prospective
Customers, and that the Company’s Confidential Information and relationships with its Customers, Vendors and Prospective Customers
constitute significant and valuable assets of the Company.

 

(e) Non-Disclosure
of Confidential Information. During and after employment under this Agreement, including but not limited to the Non-Compete Period,
the Executive shall not, directly or indirectly, without the prior written consent of the Board of the Company, or a person duly authorized
thereby, other than a person to whom disclosure is reasonably necessary or appropriate in connection with the performance by the Executive
of the duties of the Executive as an employee of the Company, as may be required by law or in response to a court order or a request by
a regulatory or administrative body, or as may be necessary to enforce any agreement between the Company and Executive, disclose or use
for the benefit of herself or any other person, corporation, partnership, joint venture, association, or other business organization,
any of the trade secrets or Confidential Information of the Company. If the Executive is legally required to disclose any Confidential
Information or trade secrets, to the extent practicable, the Executive will provide the Company with written notice. Notice shall be provided
in accordance with Section 15 below.

 

(f) Need
for Restrictions. The Executive acknowledges and agrees that each of the restrictive covenants contained in this Section 10 is reasonable
and necessary to protect the legitimate business interests of the Company, including, without limitation, the need to protect the Company’s
trade secrets and Confidential Information and the need to protect its relationships with its Customers, Prospective Customers, Vendors,
and agents. The Executive also acknowledges and agrees, as set forth in Subsection 10(g) below, that the Company may obtain a temporary,
preliminary, and/or permanent injunction to restrain any violations of, or otherwise enforce, the restrictive covenants contained in Section
10.

 

(g) Breach
of Restrictive Covenants. In the event of a breach or threatened breach by the Executive of any restrictive covenant set forth in
Section 10, the Executive agrees that such a breach or threatened breach would cause irreparable injury to the Company, and that, if the
Company shall bring legal proceedings against the Executive to enforce any restrictive covenant, the Company shall be entitled to seek
all available civil remedies, at law or in equity, including, without limitation, an injunction without posting a bond. In any action
resulting from a breach of this Agreement, the prevailing party shall be entitled to recover his or its attorneys’ fees and costs.

 

(h) Successors
and Assigns. the Company and its successors and assigns may enforce these restrictive covenants.

 

(i) Severability.
If any portion of any covenant in this Section 10 or its application is construed to be invalid, illegal, or unenforceable, then the other
portions and their application shall not be affected thereby and shall be enforceable without regard thereto. If any of the Covenants
is determined to be unenforceable because of its scope, duration, geographical area or similar factor, then the court making such determination
shall have the power to reduce or limit such scope, duration, area or other factor, and such Covenant shall then be enforceable in its
reduced or limited form. All provisions of this Section 10 shall survive the term of this Agreement and Executive’s employment with
the Company.

 

    8

     

    

 

11. Return
of Company Property. All of the Company’s and its subsidiaries’ and affiliates’ products, Customer correspondence,
internal memoranda, designs, sales brochures, training manuals, project files, price lists, Customer and Vendor lists, prospectus reports,
Customer or Vendor information, sales literature, territory printouts, call books, notebooks, textbooks e-mails and Internet access, and
all other like information or products, including all copies, duplications, replications and derivatives of such information or products,
acquired by the Executive while in the employ of the Company, whether prepared by the Executive or coming into the Executive’s possession,
shall be the exclusive property of the Company and shall be returned immediately to the Company upon the expiration or termination of
this Agreement for any reason or upon request by the President of the Company or the Board of the Company. The Executive also shall return
immediately return any the Company issued property including, but not limited to, laptops, computers, thumb drives, removable media devices,
flash drives, smartphones, cellular phones, iPads and other devices upon the expiration or termination of this Agreement for any reason
or upon request by the President of the Company or the Board. The Executive’s obligations under this Section 11 shall exist whether
or not any of these items or materials contain Confidential Information or trade secrets. The parties hereto shall comply with all applicable
laws and regulations regarding retention of and access to this Agreement and all books, documents and records in connection therewith.
The Executive shall provide the Company with a signed certificate evidencing that all such property has been returned, and that no such
property or Confidential Information or trade secret has been retained by the Executive in any form.

 

12. Executive
and Company Representations. The Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance
of this Agreement by the Executive does not and will not conflict with, breach, violate or cause a default under any contract, agreement,
instrument, order, judgment or decree to which the Executive is a party or by which she is bound, and (ii) upon the execution and delivery
of this Agreement by the Company, this Agreement shall be a valid and binding obligation of the Executive, enforceable in accordance with
its terms. The Company hereby represents and warrants to the Executive that (i) the execution, delivery and performance of this Agreement
by the Company does not and will not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order,
judgment or decree to which the Company is a party or by which it is bound and (ii) upon the execution and delivery of this Agreement
by the Executive, this Agreement shall be a valid and binding obligation of the Company, enforceable in accordance with its terms.

 

13. Arbitration.
The Parties agree that, except for any rights that any party may have to apply to a court of competent jurisdiction for specific performance
or injunctive relief, all disputes shall be submitted solely and exclusively to final and binding arbitration before a single, neutral
arbitrator before the American Arbitration Association (“AAA”), in accordance with the AAA’s prevailing National Rules
for the Resolution of Commercial Disputes. Such arbitration shall proceed in Dallas, Texas, and the Demand for Arbitration shall only
be filed with the AAA after the initiating party provides the other party(s) with at least thirty (30) days’ advance notice of the
contemplated demand. Judgment upon the award rendered by the arbitrator may be entered in any court of competent jurisdiction. The initiating
party shall advance the arbitration filing fee, and all other AAA administrative fees shall be shared equally by the parties to such a
dispute, subject to apportionment by the arbitrator in the award. Each party shall be solely responsible for its own costs and attorneys’
fees. The foregoing notwithstanding, in the event that either party shall institute litigation in court for purposes of seeking injunctive
relief or specific performance then all claims, counterclaims or causes of action that one party may have against the other shall be resolved
in such litigation and the foregoing requirement that the parties shall resolve their disputes by mandatory arbitration shall be null
and void.

 

    9

     

    

 

14. Survival.
The provisions of Sections 7 through 25, along with any other provisions necessary or desirable to accomplish the purposes of such sections,
shall survive and continue in full force in accordance with their terms notwithstanding any termination of the Employment Period. The
obligation of the Company to make payments to the Executive under Section 7(b) hereof, and the Executive’s right to retain the same,
are expressly conditioned upon the Executive’s continued full performance of his obligations hereunder. Upon termination by either
the Executive or the Company, all rights, duties and obligations of the Executive and the Company to each other shall cease, except as
otherwise expressly provided in this Agreement.

 

15. Notices.
All notices, requests, demands, consents or other communications required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been duly given if and when: (i) delivered personally, (ii) three (3) business days after being mailed by
first class certified mail, return receipt requested, postage prepaid, or (iii) one (1) business day after being sent by a nationally
recognized overnight courier service, delivery charges prepaid, or (iv) one (1) business day after being sent by email or facsimile to
the other party at the addresses stated herein or to such other address of which either party may give notice to the other in accordance
with this Section.

 

	 	If to the Company:	General Counsel
	 	 	Attn: Kevin M. Sherlock
	 	 	COMSovereign Holding Corp.
	 	 	5000 Quorum Drive, Suite 400
	 	 	Dallas, TX 75254
	 	 	Email:  Legal@COMSovereign.com
	 	 	 
	 	With a copy to:	Pryor Cashman LLP
	 	 	7 Times Square
	 	 	New York, New York 10036
	 	 	Attention:  Eric M. Hellige
	 	 	Facsimile:  (212) 798-6380
	 	 	Email:  ehellige@pryorcashman.com
	 	 	 
	 	If to the Executive:	Frances M. Jandjel
	 	 	17406 Pinecreek Hollow Lane
	 	 	Houston, TX 77095
	 	 	Email:  franmjand@gmail.com

 

16. Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule
in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but
this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had
never been contained herein.

 

    10

     

    

 

17. Complete
Agreement. This Agreement embodies the complete agreement and understanding among the Parties with respect to the subject matter hereof
and supersede and preempt any prior understandings, agreements or representations by or among the Parties, written or oral, which may
have related to the subject matter hereof, including without limitation the employment agreement between the Executive and the Company.

 

18. Counterparts.
This Agreement may be executed in separate counterparts, including via facsimile, each of which is deemed to be an original and all of
which taken together constitute one and the same agreement.

 

19. Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by the Executive, the Company and their
respective heirs, successors and permitted assigns. The Executive may not assign his rights or delegate his obligations hereunder. The
Company may assign all or any part of this Agreement to any third party that shall (i) acquire the Company, or any parent of the Company,
in a merger, (ii) acquire a majority of the capital stock of the Company, or any parent of the Company, or (iii) purchase all or substantially
all of the Company’s assets (or all or substantially all of the assets of the portion of the Company’s business that the Executive’s
employment was most associated with), provided, however, that in each case the Company shall provide the Executive with written notice
thereof.

 

20. 
Key Man Insurance. While the Executive is employed by the Company or any of its subsidiaries, the Company may at any time effect
insurance on the Executive’s life and/or health in such amounts and in such form as the Company may in its sole discretion decide.
Except as provided under the applicable terms of a policy or other arrangement, the Executive will not have any interest in such insurance,
but shall, if the Company requests, submit to such medical examinations, supply such information and execute such documents as may be
required in connection with, or so as to enable the Company to effect, such insurance.

 

21. Choice
of Law; Jurisdiction. This Agreement shall be governed, construed and enforced in accordance with the laws of the State of Texas.
All suits, actions or other proceedings seeking to enforce, or otherwise arising in connection with, this Agreement shall be brought in
the state or federal courts located in the Dallas, Texas. Each of the Parties irrevocably consents to the exclusive jurisdiction of the
foregoing courts in such matters and irrevocably waives any objection such Party may otherwise have against such jurisdiction.

 

22. Amendment
and Waiver. The provisions of this Agreement may be amended or waived only with the express, prior, written consent of the Company
and the Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity,
binding effect or enforceability of this Agreement.

 

23. Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument representing the agreement of the parties hereto.

 

24. Electronic
Document. A copy of this Agreement or signature page hereto signed and transmitted by facsimile machine, as an attachment to an e-mail
or by other electronic means (collectively an “Electronic Document”), shall be treated as an original document. The
signature of any party thereon, for purposes hereof, is to be considered an original signature, and the Electronic Document transmitted
is to be considered to have the same binding effect as an original signature on an original document. No party shall raise the use of
an Electronic Document or the fact that a signature was transmitted through the use of a facsimile machine, e-mail or other electronic
means as a defense to the enforcement of this Agreement or any amendment or other document executed in compliance with this Agreement.

 

    11

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have executed this Agreement as of the date first above written.

 

 

	 	COMSOVEREIGN HOLDING CORP.:
	 	 	 
	 	By:	/s/ Daniel L. Hodges
	 	Name:	Daniel L. Hodges
	 	Title:	Chief Executive Officer
	 	 	 
	 	EXECUTIVE:
	 	 	 
	 	/s/ Frances M. Jandjel
	 	Frances M. Jandjel

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]